

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2006207463 B2**

- (54) Title
Method for producing a compound of interest in a filamentous fungal cell
- (51) International Patent Classification(s)
C12N 9/20 (2006.01) **C12N 15/80** (2006.01)
C12N 9/30 (2006.01)
- (21) Application No: **2006207463** (22) Date of Filing: **2006.01.24**
- (87) WIPO No: **WO06/077258**
- (30) Priority Data
- (31) Number (32) Date (33) Country
05100408.3 **2005.01.24** **EP**
- (43) Publication Date: **2006.07.27**
(44) Accepted Journal Date: **2011.03.17**
- (71) Applicant(s)
DSM IP Assets B.V.
- (72) Inventor(s)
Stam, Hein;Van Peij, Noel Nicolaas Maria Elisabeth;Roubos, Johannes Andries;Donkers, Serge Petrus
- (74) Agent / Attorney
Phillips Ormonde Fitzpatrick, 367 Collins Street, Melbourne, VIC, 3000
- (56) Related Art
WO 2003/085114 A1
WO 2003/070957 A2
EP 1 231 272 A2

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 July 2006 (27.07.2006)

PCT

(10) International Publication Number
WO 2006/077258 A1

(51) International Patent Classification:

C12N 9/20 (2006.01) C12N 15/80 (2006.01)
C12N 9/30 (2006.01)

(21) International Application Number:

PCT/EP2006/050398

(22) International Filing Date: 24 January 2006 (24.01.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

05100408.3 24 January 2005 (24.01.2005) EP

(71) Applicant (for all designated States except US): **DSM IP ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROUBOS, Johannes, Andries** [NL/NL]; Fortuinstraat 10, NL-2611 LW Delft (NL). **DONKERS, Serge, Petrus** [NL/NL]; Culhemiusstraat 5, NL-3222 CE Hellevoetsluis (NL). **STAM, Hein** [NL/NL]; Antilope 85, NL-1273 GC Huizen (NL). **VAN PEIJ, Noël, Nicolaas, Maria, Elisabeth** [NL/NL]; Straat Van Ormoes 48, NL-2622 KA Delft (NL).

(74) Agent: **PALLARD, Caroline, Chantal, Patricia**; DSM Intellectual Property, PP 600-0240, P.O. Box 1, NL-2600 MA Delft (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR PRODUCING A COMPOUND OF INTEREST IN A FILAMENTOUS FUNGAL CELL

(57) Abstract: The invention relates to a nucleotide sequence comprising: a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon; and optionally said nucleotide sequence comprises control sequences such as: one translational termination sequence orientated in 5' towards 3' direction selected from the following list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or one translational initiator coding sequence orientated in 5' towards 3' direction selected from the following list of sequences: gctnccyycc, using ambiguity codes for nucleotides: v (A/C/G); n (A/C/G/T), preferably 5'-GCT TCC TTC-3'. The invention further relates to a consensus translational initiator sequence: 5'-mwChkyCAmv-3', preferably the translational initiator sequence is selected from the list consisting of: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3'.



WO 2006/077258 A1

METHOD FOR PRODUCING A COMPOUND OF INTEREST IN A FILAMENTOUS FUNGAL CELL

5

Field of the invention

The present invention relates to a method for producing a compound of interest in a filamentous fungal cell, wherein the nucleotide sequence encoding the compound of interest and/or control nucleotide sequences operatively associated thereto have been modified to get improved expression of the nucleotide sequence encoding the compound of interest and/or improved production of the compound of interest.

10

Background of the invention

The present invention relates to improved methods for producing a compound of interest. Numerous approaches have been applied to date in generating strains for protein over-expression and/or production. This includes, but is not limited to, making strains with multi-copies of the gene encoding the compound of interest and applying strong promoter sequences.

15

Each specific amino acid is encoded by a minimum of one codon and a maximum of six codons. Prior research has shown that codon usage in genes encoding the cell's polypeptides is biased among species (Kanaya, S, Y. Yamada, Y. Kudo and T. Ikemura (1999) Studies of codon usage and tRNA genes at 18 unicellular organisms and quantification of *Bacillus subtilis* tRNAs: gene expression level and species-specific diversity of codon usage based on multivariate analysis. *Gene* 238:143-155). Prior publications disclose optimization of codon use in a given host cell to improve polypeptide production (as example see WO 97/11086). More specifically, WO 03/70957 describes optimized codon use in filamentous fungi for producing plant polypeptides. In all these cases of 'classic' codon optimization, a native codon has been substituted by the most frequent codon from a reference set of genes, whereas the rate of codon translation for each amino acid is designed to be high (optimized). However, this 'classic' codon optimization neglects the other codons for which tRNAs are still available.

20

25

30

Recently, in WO 03/85114 a harmonization of codon use was described which takes into effect the distribution of optimal and non-optimal codons in genes, assuming that these effect protein folding. Using this method of harmonization of codon use for a gene results in the substitution of good (bad) codons in the donor organism by good (bad)

ones in the host organism. However, this method of codon harmonization (WO 03/085114) neglects non-optimal codons since they are not replaced by more optimal ones. Additionally, the method cannot be applied to homologous genes.

Another publication describes an additional way to improve polypeptide production in a host cell by using an improved consensus translational initiator sequence (US 6,461,837 B1); the consensus sequence 5'-nyCnnhCACC(ATG)-3' is claimed.

There is still a need for improved methods for producing a polypeptide in a filamentous fungal cell.

Description of the Figures

Figure 1 depicts a plasmid map of expression vector pGBFIN-30. Indicated are the *glaA* flanking regions relative to the *glaA* promoter with the unique *SfiI* and *EcoRI* cloning sites in the glucoamylase promoter followed by the *HindIII* and *NruI* cloning sites. The pGBFIN-30 vector is originating from pGBFIN-23 (which construction is described in WO99/32617), with the *Ascl* - *XhoI* sites replaced by a single *NruI* restriction site. The *E. coli* DNA can be removed by digestion with restriction enzyme *NotI*, prior to transformation of the *A. niger* strains.

Figure 2 depicts a plasmid map of expression vector pGBFINPLA-1a. Figure 2 also provides a representative map for plasmid pGBFINPLA-1b and pGBFINPLA-1c. Indicated are the *glaA* flanking regions relative to the *glaA* promoter and the *A. oryzae* genomic *pla1* gene encoding phospholipase A1. The *E. coli* DNA can be removed by digestion with restriction enzyme *NotI*, prior to transformation of the *A. niger* strains..

Figure 3 depicts a plasmid map of expression vectors pGBFINPLA-1d through pGBFINPLA-1h. Indicated are the *glaA* flanking regions relative to the variant sequences of the *glaA* promoter and the *A. oryzae* genomic *pla1* gene encoding phospholipase A1. The *E. coli* DNA can be removed by digestion with restriction enzyme *NotI*, prior to transformation of the *A. niger* strains.

Figure 4 depicts a plasmid map of expression vector pGBFINFUA-1. Figure 4 also provides a representative map for plasmid pGBFINFUA-2 and pGBFINFUA-3. All clones originate from the pGBFIN-12 (described in WO99/32617) expression vector. Indicated are the *glaA* flanking regions relative to the variant sequences of the *amyA* promoter and the *A. niger* *amyA* cDNA sequence encoding alpha-amylase. The *E. coli* DNA can be

removed by digestion with restriction enzyme *NotI*, prior to transformation of the *A. niger* strains.

Figure 5 depicts a schematic representation of integration through single homologous recombination. The expression vector comprises the selectable *amdS* marker, and the *glaA* promoter connected to the *pla1* gene. These features are flanked by homologous regions of the *glaA* locus (3' *glaA* and 3'' *glaA*, respectively) to direct integration at the genomic *glaA* locus.

Figure 6 depicts an alignment of the native *pla1* coding sequence, the native *pla1* genomic sequence and a synthetic optimized *pla1* coding sequence. The introns in the genomic sequence are indicated in the *pla1* genomic sequence. The codons, which have been changed in the modified *pla1* coding sequence, are indicated with boxes. The nucleotides, which have been modified, are indicated in gray.

Figure 7 depicts phospholipase A1 activity in culture broth for *A. niger* strains expressing eight different constructs (pGBFINPLA-1a-h). Depicted is the average phospholipase A1 activity in culture broth of *A. niger* strains expressing a native (pGBFINPLA-1a) or modified *pla1* constructs (pGBFINPLA-1b-h), wherein the translation initiation sequence and/or the translation termination sequence and/or the codon usage have been modified according the method of the invention. Phospholipase activities are depicted in arbitrary units [AU] and are the average of at least five independently isolated and cultivated transformants, named as indicated (Table 6), measured after the cultivation time as indicated.

Figure 8 depicts Phospholipase A1 activity in culture broth for *A. niger* strains expressing three different constructs. Depicted is the phospholipase A1 activity in culture broth of three *A. niger* strains expressing a native (pGBFINPLA-1a) or modified *pla1* construct, wherein the translation initiation sequence and the translation termination sequence (pGBFINPLA-1b) and the translation initiation sequence, the translation termination sequence and the codon usage (pGBFINPLA-1e) were modified according a method of the invention. Phospholipase activities are depicted in arbitrary units [AU] for 2-copy *pla1* transformants, named as indicated (Table 6), and measured after the cultivation time indicated.

Figure 9 depicts Alpha-amylase activity in culture broth for *A. niger* strains expressing three different constructs. Depicted is the alpha-amylase activity in culture broth of *A. niger* strains expressing a native (pGBFINFUA-1) or modified *amyA* construct, wherein the translation initiation sequence and the translation termination sequence were

modified (pGBFINFUA-2) and the translation initiation sequence, the translation termination sequence and the codon usage were modified (pGBFINFUA-3) according a method of the invention. Alpha-amylase activities are depicted in relative units [AU], with the average of the 7 one-copy strains of the FUA1 group of 10 strains at day 4 set at 100%. The ten transformants per group indicated are independently isolated and cultivated transformants, named as indicated in Table 9, and measured the the cultivation time as indicated.

Detailed description of the invention

A new approach to improve production of a compound of interest in a filamentous fungal cell is proposed based on modification of the protein encoding or coding sequence and optionally the associated 'non-coding' or control sequences that might have impact on translation efficiency and/or efficiency of production of the compound of interest.

Nucleotide sequences

According to a first aspect of the invention, there is provided a nucleotide sequence comprising:

- a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon; and optionally said nucleotide sequence comprising control sequences such as:
 - one translational termination sequence orientated in 5' towards 3' direction selected from the following list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or
 - one translational initiator coding sequence orientated in 5' towards 3' direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCTC; and GCTTCCTTC, preferably GCT TCC TTC.

Table 1: Optimal filamentous fungal codon frequency for synonymous codons in %

	.T.	.C.	.A.	.G.	
T . .	Phe 0	Ser 21	Tyr 0	Cys 0	. . T
T . .	Phe 100	Ser 44	Tyr 100	Cys 100	. . C
T . .	Leu 0	Ser 0	Stop 100	Stop 0	. . A
T . .	Leu 13	Ser 14	Stop 0	Trp 100	. . G
C . .	Leu 17	Pro 36	His 0	Arg 49	. . T
C . .	Leu 38	Pro 64	His 100	Arg 51	. . C
C . .	Leu 0	Pro 0	Gln 0	Arg 0	. . A
C . .	Leu 32	Pro 0	Gln 100	Arg 0	. . G
A . .	Ile 27	Thr 30	Asn 0	Ser 0	. . T
A . .	Ile 73	Thr 70	Asn 100	Ser 21	. . C
A . .	Ile 0	Thr 0	Lys 0	Arg 0	. . A
A . .	Met 100	Thr 0	Lys 100	Arg 0	. . G
G . .	Val 27	Ala 38	Asp 36	Gly 49	. . T
G . .	Val 54	Ala 51	Asp 64	Gly 35	. . C
G . .	Val 0	Ala 0	Glu 0	Gly 0	. . A

	0	0	26	16	
	Val	Ala	Glu	Gly	
G . .	19	11	74	0	. . G

According to a preferred embodiment, said nucleotide sequence is a sequence wherein the optimized codon frequency of said synonymous nucleotide coding sequence comprised in said nucleotide sequence is such that at least one native codon, preferably at least two native codons, more preferably at least three native codons, more preferably at least four native codons, more preferably at least five native codons, more preferably at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, and most preferably at least 95% of the native codons have been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon.

According to a more preferred embodiment, said nucleotide sequence is a sequence wherein the optimized codon frequency of said synonymous nucleotide coding sequence comprised in said nucleotide sequence is such that at least one native codon, preferably at least two native codons, more preferably at least three native codons, more preferably at least four native codons, more preferably at least five native codons, more preferably at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, and most preferably at least 95% of the native codons have been exchanged with a synonymous codon, the synonymous codon changing the codon frequency such that the value of the absolute difference between the percentage for said synonymous codon in said frequency and the listed optimal percentage becomes smaller after modification, applying the following list of optimal percentages: cysteine by TGC (100%); phenylalanine by TTC (100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by AAC (100%); glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by GCT (38%), GCC (51%), or GCG (11%); aspartate by GAC (64%); glutamate by GAG (74%); glycine by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC (73%); leucine by TTG (13%), CTT (17%), CTC (38%), CTG (32%); proline by CCT (36%), CCC (64%); arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG (14%), AGC (21%); threonine by ACT (30%), ACC (70%) and/or valine by GTT (27%), GTC (54%), GTG (19%).

According to an even more preferred embodiment, said nucleotide sequence is a sequence wherein the codon fitness of said synonymous nucleotide coding sequence with optimized codon frequency comprised in said nucleotide sequence has a fitness value that is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%, and most preferable >98%, where the codon fitness is calculated by means of the following function:

$$fit_c(g) = 100 - \frac{1}{|g|} \cdot \sum_{k=1}^{|g|} |r_c^{target}(c(k)) - r_c^g(c(k))| \cdot 100$$

where g symbolizes a nucleotide coding sequence, $|g|$ its length, $g(k)$ its k -th codon, $r_c^{target}(c(k))$ is a desired ratio of codon $c(k)$ and $r_c^g(c(k))$ an actual ratio in the nucleotide coding sequence g .

In the context of the invention, both nucleotide coding sequence and control sequence are herein named native or wild type when one refers to these sequences before the method of the invention has been applied to. Once having been modified by the invention, they would be named modified or synonymous sequences. Consequently, synonymous sequences would generally be recognized as recombinant sequences. Incidentally, a sequence occurring in nature may be identical to the synonymous sequence.

In the context of the invention, a nucleotide coding sequence and a synonymous nucleotide coding sequence may directly encode a compound of interest to be produced. The term compound of interest is defined later in the section "Production of a compound of interest". An example of a compound of interest that is directly encoded by a (synonymous) nucleotide coding sequence is a polypeptide, preferably, the polypeptide is an enzyme, more preferably an enzyme that is secreted outside the cell. Alternatively, the compound encoded by the (synonymous) nucleotide coding sequence may not be the compound of interest *per se*, but may *inter alia* be involved in the production of the compound of interest. In this case, the compound encoded by the (synonymous) nucleotide coding sequence can be, but is not limited to, an intracellular enzyme involved in the production of a metabolite, a transporter, a transcription factor, a structural protein, a chaperone or the product of a housekeeping gene.

According to a further aspect of the present invention, there is provided a nucleotide sequence comprising:

- a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon;

wherein the optimized codon frequency is such that at least three native codons; more preferably 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, and most preferably at least 95% of the native codons have been exchanged with a synonymous codon, the synonymous codon changing the codon frequency such that the value of the absolute difference between the percentage for said synonymous codon in said frequency and the listed optimal percentage becomes smaller after modification, applying the following list of optimal percentages: cysteine by TGC (100%); phenylalanine by TTC (100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by AAC (100%); glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by GCT (38%) GCC (51%), or GCG (11%); aspartate by GAC (64%); glutamate by GAG (74%); glycine by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC (73%); leucine by TTG (13%), CTT (17%), GTC (38%), CTG (32%); proline by CCT (36%), CCC (64%); arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG (14%), AGC 21% threonine by ACT (30%), ACC (70%) and/or valine by GTT (27%), GTC (54%), GTG (19%);

and optionally said nucleotide sequence comprising control sequences such as:

- one translational termination sequence orientated in 5' towards 3' direction selected from the following list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or

- one translational initiator coding sequence orientated in 5' towards 3' direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTGCCCCC; GCTCCCTCC; GCTCCCCTTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCTTCCTTC.

In the context of the invention the term "codon" generally refers to a nucleotide triplet, which codes for an amino acid. As used herein "synonymous codon" refers to a

codon which does not have the identical nucleotide sequence, but which encodes the identical amino acid (AA). The term "codon frequency", "codon bias", or "codon usage" is defined as the frequency at which the different corresponding codons are used in a coding sequence. Codon usage is based on the fact that several codons in a coding sequence encode the same amino acid, but that the frequency of the different codons encoding said amino acid may vary between various coding sequences.

A nucleotide coding sequence (encoding a polypeptide) that is homologous or heterologous to the host cell used for production may originate for example from a virus, a prokaryote, a fungus, a filamentous fungus, other eukaryotes and higher eukaryotes, like mammals, human and plants. This (native) nucleotide coding sequence is modified according to the optimal codon frequency as described in Table 1 (and further disclosed in paragraph "Calculation of "optimized codon frequency" or "optimized codon usage" using Table 1"), generating a synonymous nucleotide sequence. The native, coding sequence may be selected from the group of:

- a wild-type nucleotide sequence coding for a predetermined amino acid sequence,
- a back-translation of a natural occurring amino acid sequence using random choice for the codons,
- a non-naturally occurring amino acid sequence, displaying homology to a known amino acid sequence, e.g. a shuffled sequence,
- part of the sequences mentioned her above, e.g. to be used in fusion sequences.

The synonymous nucleotide coding sequence with optimized codon usage, is preferably expressed in an *Aspergillus*, *Trichoderma*, *Fusarium*, *Chrysosporum* or *Penicillium* host cell. More preferably the synonymous nucleotide coding sequence is expressed in an *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus sojae*, *Aspergillus terreus*, *Trichoderma reesei*, *Chrysosporum lucknowense* or *Penicillium chrysogenum* host cell. A most preferred *Aspergillus niger* host cell is CBS513.88 or derivatives thereof. Preferably, the expression of the product encoded by the synonymous coding sequence present is enhanced as compared to the production of the corresponding native coding sequence, said corresponding nucleic acid construct being present in the same copy number in a corresponding filamentous fungal host cell. Preferably, the modification of the nucleotide coding sequence, (resulting in a synonymous nucleotide

coding sequence of the invention) results in an increase of at least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400% more preferably at least 500% of the yield of the compound of interest produced by the filamentous fungal host cell of the invention comprising a given copy number of the synonymous nucleotide coding sequence, as compared to the production of the native nucleotide coding sequences being present in the same copy number in a corresponding filamentous fungal host cell.

The increase in yield of the compound of interest to be produced may be determined by measuring the amount of compound produced by the filamentous fungal host cell of the invention and comparing it to the compound of interest produced by the corresponding filamentous fungal host cell. Determining the yield of compound of interest produced may be performed by measuring *inter alia* the amount of mRNA transcribed from the (synonymous) nucleotide coding sequence, the amount of polypeptide encoded by the mRNA, or the amount of compound (e.g. metabolite) in which' production the polypeptide encoded by the synonymous nucleotide coding sequence is involved with. Examples of methods known to the skilled person to determine the amount of mRNA include, but are not limited to Northern blot, Quantitative PCR, Real Time PCR, and micro-array analyses. The amount of polypeptide can *inter alia* be determined using protein measurement assays known to the skilled person. When the polypeptide is an enzyme, the amount of polypeptide can be measured using an activity assay specific for the concerned enzyme. The skilled person will know which assay to select for a specific enzyme. A preferred assay to determine the yield of the compound of interest to be produced is an activity assay specific for the concerned enzyme.

Considering the optimal codon usage as defined in Table 1 and codon bias between the genes of an organism, a native coding nucleotide sequence encoding a homologous polypeptide may also be considered subject to codon optimization and provide a higher yield for the homologous polypeptide than would the expression of the native nucleotide sequence in the same host.

In the context of this invention, a nucleotide coding sequence or coding sequence is defined as a nucleotide sequence encoding a polypeptide. The boundaries of the nucleotide coding sequence are generally determined by the ATG start codon located at the beginning of the open reading frame at the 5' end of the mRNA and a stop codon located just downstream of the open reading frame at the 3' end of the mRNA. A

nucleotide coding sequence can include, but is not limited to, DNA, cDNA, RNA, and recombinant nucleic acid (DNA, cDNA, RNA) sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. A nucleotide
5 coding sequence comprises a translational initiator coding sequence, and optionally a signal sequence.

In order to attain expression of the nucleotide coding sequence, the nucleotide coding sequence is preferably combined with a control sequence. In the context of the
10 invention, a control sequence is defined as a nucleotide sequence necessary or advantageous for expression of the nucleotide sequence encoding a polypeptide. When present together, the control sequence is operatively associated to the nucleotide coding sequence. The term "control sequence" includes all genetic elements necessary or advantageous for expression of a nucleotide coding sequence. Each control sequence
15 may be native or foreign to the nucleotide coding sequence. Control sequences include, but are not limited to, a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, a translational initiator sequence, a translational initiator coding sequence, a translational transcription terminator and a transcription terminator sequence. The control sequences may be provided with linkers, e.g., for the purpose of
20 introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleotide sequence encoding a polypeptide.

The term "operatively associated" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to a (synonymous)
25 nucleotide coding sequence such that the control sequence directs the expression of the (synonymous) nucleotide coding sequence.

In the context of this invention, the term "translational initiator coding sequence" is defined as the nine nucleotides immediately downstream of the initiator or start codon of
30 the open reading frame of a DNA coding sequence. The initiator or start codon encodes for the AA methionine. The initiator codon is typically ATG, but may also be any functional start codon such as GTG. The term "consensus translational initiator coding sequence" is defined herein as the nine nucleotides immediately downstream of the initiator codon of the open reading frame of a DNA coding sequence and having the following DNA

sequence: 5'-GCTnCCyyC-3' (i.e. SEQ ID NO. 20), using ambiguity codes for nucleotides y (C/T) and n (A/C/G/T). This leads to 16 variants for the translational initiator coding sequence: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; GCTTCCTTC. Preferably, the translational initiator coding sequence has the nucleic acid sequence: 5'- GCT TCC TTC -3' (i.e. SEQ ID NO. 21).

Using a consensus translational initiator coding sequence, the following AA are allowed at the AA positions mentioned: alanine at +2, alanine, serine, proline, or threonine at +3, and phenylalanine, serine, leucine or proline at +4 position in the polypeptide that is encoded. In the present invention, the consensus translational initiator coding sequence may be foreign to the nucleic acid sequence encoding the polypeptide to be produced. Alternatively, the consensus translational initiator may be native to the fungal host cell.

In the context of this invention, the term "translational termination sequence" is defined as the four nucleotides starting from the translational stop codon at the 3' end of the open reading frame or nucleotide coding sequence and oriented in 5' towards 3' direction. Preferably, the translational termination sequence is selected from the following list of sequences: 5'-TAAG-3', 5'- TAGA-3' and 5'-TAAA-3'. More preferably, the translational termination sequence is: 5'-TAAA-3'.

The term "optimized codon frequency" or "optimized codon usage" as used herein refers to a native nucleotide coding sequence, which has been modified wholly or partly to give a synonymous nucleotide coding sequence according to the codon usage as described in Table 1 (and further disclosed in paragraph "Calculation of "optimized codon frequency" or "optimized codon usage" using Table 1"). Optimizing codon frequency can be used to improve any coding sequence for any given polypeptide to be produced in any filamentous fungal species as host cell. Preferably, the filamentous fungal host cell is an *Aspergillus*, *Trichoderma*, *Fusarium*, *Chrysosporum* or *Penicillium* host cell. More preferably the filamentous fungal host cell is an *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus sojae*, *Aspergillus terreus*, *Trichoderma reesei*, *Chrysosporum lucknowense* or *Penicillium chrysogenum* host cell. A most preferred *Aspergillus niger* host cell is CBS513.88 or derivatives thereof. A more exhaustive list of the preferred host cells is given under the section "Host cells".

When the amino acid sequence of a polypeptide sequence has been determined, a nucleotide sequence encoding the polypeptide with optimized codon frequency for expression in the host cell or synonymous nucleotide coding sequence can be synthesized in which one or more of the native codons have been exchanged with a synonymous codon encoding the same amino acid, said synonymous codon having a higher frequency in the codon usage as defined in Table 1 (and further disclosed in paragraph "Method for producing a nucleotide sequence; calculation of the optimized codon frequency" using Table 1").

A nucleotide sequence encoding a polypeptide or synonymous coding sequence is considered to have an optimized codon frequency when at least one native codon, at least two native codons, at least three native codons, at least four native codons, at least five native codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, or preferably at least 95% of the native codons have been exchanged with a synonymous codon, the synonymous codon encoding the same amino acid as the native codon and having a higher frequency in the codon usage as defined in Table 1 than the native codon.

A nucleotide sequence encoding a polypeptide or synonymous coding sequence is considered to have an optimized codon frequency when at least one native codon, at least two native codons, at least three native codons, at least four native codons, at least five native codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, or preferably at least 95% of the native codons have been exchanged with a synonymous codon, the synonymous codon changing the codon frequency such that the value of the absolute difference between the percentage for said codon in said frequency and listed optimal percentage becomes smaller after modification, applying the following list of optimal percentages: cysteine by TGC (100%); phenylalanine by TTC (100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by AAC (100%); glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by GCT (38%), GCC (51%), or GCG (11%); aspartate by GAC (64%); glutamate by GAG (74%); glycine by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC (73%); leucine by TTG (13%), CTT (17%), CTC (38%), CTG (32%); proline by CCT (36%), CCC (64%); arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG (14%),

AGC (21%); threonine by ACT (30%), ACC (70%) and/or valine by GTT (27%), GTC (54%), GTG (19%).

Codon fitness is defined to be the difference of the actual codon ratios in the gene and the target codon ratios, normalized for the number of occurrences of every codon.

5 Let $r_{sc}^{target}(c(k))$ be the desired ratio (or frequency) of codon c_k and $r_{sc}^g(c(k))$ as before the actual ratio in the gene g , then the single codon fitness is defined as:

$$fit_c(g) = 100 - \frac{1}{|g|} \cdot \sum_{k=1}^{|g|} |r_c^{target}(c(k)) - r_c^g(c(k))| \cdot 100$$

Thus, codon fitness $\{fit_c(g)\}$ can reach values between 0 and 100% with the optimal sequence being close to 100%. Consequently, a synonymous nucleotide coding
 10 sequence is considered to have an optimized codon frequency when the codon fitness value of the synonymous coding sequence is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%, and most preferable >98%.

The nucleotide sequence of the invention may be a synthetic nucleotide
 15 sequence. As used herein, the term "synthetic" gene, DNA construct, nucleic acid, polynucleotide, primer, or the like means a nucleotide sequence that is not found in nature; in other words, not merely a heterologous sequence to a particular organism, but one which is heterologous in the sense that it has been designed and/or created in a laboratory, and has been altered in some way that it does not have an identical nucleotide
 20 (or possibly AA) sequence to the one of its naturally occurring source, template or homologue. A synthetic nucleic acid or AA sequence as used herein can refer to a theoretical sequence or a tangibly, physically created embodiment. It is intended that synthetic sequences according to the invention are included in the invention in any form, e.g. paper or computer readable and physically created nucleic acid sequences, proteins,
 25 peptides, fused peptides or multi-peptides.

Alternative, a naturally occurring nucleotide sequence may display the features of the invention. The use of such sequence is considered to be encompassed within the invention.

30 The term "synthetic nucleotide construct" or "synthetic nucleic acid" can include nucleic acids derived or designed from wholly artificial amino acid sequences or nucleic acid sequences with single or multiple nucleotide changes compared to the naturally occurring sequence. These "synthetic DNA constructs" can be created by random or

directed mutagenesis, DNA shuffling methods, DNA reassembly methods, gene synthesis, or by any means known to one skilled in the art (see for example Young and Dong, (2004), Nucleic Acids Research 32, (7) electronic access <http://nar.oupjournals.org/cgi/reprint/32/7/e59> or Gupta *et al.* (1968), Proc. Natl. Acad. Sci USA, 60: 1338-1344; Scarpulla *et al.* (1982), Anal. Biochem. 121: 356-365; Stemmer *et al.* (1995), Gene 164: 49-53).

Alternatively, a synthetic nucleotide sequence may be designed from an amino acid sequence (see example 2). Using this reverse engineering method there is no need for a naturally occurring nucleotide sequence, which may not be available. A back-translation may first be performed using random choice for the codons. Subsequently, the resulting nucleotide sequence can be optimized for codon usage.

According to another preferred embodiment, a synonymous nucleotide coding sequence with optimized codon frequency according to the invention is a reverse engineered nucleotide coding sequence, wherein the optimized codon frequency is such that at least one codon, at least two codons, at least three codons, at least four codons, at least five codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, or preferably at least 95% of the codons have a higher frequency in the codon usage as defined in Table 1 than the codon usage that is predicted by the arithmetic average (i.e., 100% in case of 1 codon, 50% in case of two codons, 33.3% in case of 3 codons, 25% in case of 4 codons, and 16.7% in case of 6 codons).

According to a more preferred embodiment, said synonymous nucleotide coding sequence with optimized codon frequency is a reverse engineered nucleotide coding sequence wherein the codon fitness of the nucleotide coding sequence has a fitness value that is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%, and most preferable >98%, where the codon fitness is the calculated by means of the following function:

$$fit_c(g) = 100 - \frac{1}{|g|} \cdot \sum_{k=1}^{|g|} |r_c^{target}(c(k)) - r_c^g(c(k))| \cdot 100$$

where g symbolizes a nucleotide coding sequence, $|g|$ its length, $g(k)$ its k -th codon, $r_c^{target}(c(k))$ is a desired ratio of codon $c(k)$ and $r_c^g(c(k))$ a calculated ratio in the nucleotide coding sequence g .

In addition to the control sequences that may be present in the nucleotide sequence of the invention, the nucleotide coding sequence may comprise a signal sequence, or signal peptide-coding region.

A signal sequence codes for an amino acid sequence linked to the amino
5 terminus of the polypeptide, which can direct the expressed polypeptide into the cell's secretory pathway. The 5'-end of the coding sequence of the nucleotide sequence may inherently contain a signal peptide-coding region naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide of interest. In that case, the translational initiator coding sequence is part of the signal
10 sequence. Alternatively, the 5'-end of the coding sequence may contain a signal peptide-coding region, which is foreign to that portion of the coding sequence that encodes the secreted protein. A foreign signal peptide-coding region may be required where the coding sequence does not normally contain a signal peptide-coding region. Alternatively, a foreign signal peptide-coding region may simply replace the natural signal peptide-
15 coding region in order to obtain enhanced secretion of the protein (s) relative to the natural signal peptide-coding region normally associated with the coding sequence. The signal peptide-coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species, the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease
20 gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide-coding region capable of directing the expressed protein into the secretory pathway of a host cell of choice may be used in the present invention. Preferred signal peptide coding regions for filamentous fungus host cells are the signal peptide coding region obtained from *Aspergillus oryzae* TAKA amylase gene (EP 238 023), *Aspergillus niger* neutral amylase gene, *Aspergillus niger* glucoamylase, the *Rhizomucor miehei* aspartic proteinase gene, the *Humicola lanuginosa* cellulase gene, *Humicola insolens* cellulase, *Humicola insolens* cutinase, the *Candida antactica* lipase B gene or the *Rhizomucor miehei* lipase gene and mutant, truncated, and hybrid signal sequence thereof.

30

In another preferred embodiment, the synonymous nucleotide coding sequence with optimized coding frequency of the invention comprises a signal sequence. According to a more preferred embodiment, the signal sequence of the invention is a signal sequence with an optimized codon frequency where at least one native codon, or at least

1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, or preferably at least 95% of the native codons have been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage than the native codon as defined in Table 1 and further disclosed in paragraph "Calculation of "optimized codon frequency" or "optimized codon usage" using Table 1". More preferably, the signal sequence of the invention comprises a translational initiator coding sequence having the following consensus DNA sequence: 5'-GCTnCCyyC-3' (i.e. SEQ ID NO. 20) or even more preferably a translational initiator coding sequence with the nucleic acid sequence: 5'- GCT TCC TTC -3' (i.e. SEQ ID NO. 21).

The nucleotide coding sequence may, before a modification of the invention is applied, contain one or more introns that contain nucleotides that are not encoding amino acids in the protein sequence. One of the steps in optimizing the expression of the coding sequence might be to use the synonymous coding sequence without introns. In example 2, the introns present in the native nucleotide sequence were not replaced in the modified constructs.

Alternatively, and according to another preferred embodiment of the invention, in a nucleotide sequence comprising a synonymous nucleotide coding sequence of the invention wherein the unmodified nucleotide coding sequence originally comprised one or more introns, at least one intron has been re-introduced in the nucleotide coding sequence, preferably, but not necessarily, at the original position. In example 1, the introns that are part of the *A. oryzae pla1* DNA sequence were replaced in the codon-optimized (synonymous) DNA sequence, which was used for expression.

Translational initiator sequences

In a second aspect, the invention relates to translational initiator sequences. A translational initiator sequence is the nucleic acid region encoding a protein start and the biological activity of a translational initiator sequence is to initiate the ribosome-mediated production of a polypeptide whose amino acid sequence is specified by the nucleotide sequence in an mRNA. In eukaryotes, the translational initiator consensus sequence (6-12 nucleotides) before the ATG is often called Kozak consensus sequence due to the initial work on this topic (Kozak, M. (1987): an analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nucl. Acid Res.* 15(20): 8125-47). The original Kozak

consensus sequence CCCGCCGCCrCC(ATG)G, including a +4 nucleotide derived by Kozak is associated with the initiation of translation in higher eukaryotes. In the context of this invention, the term "translational initiator sequence" is defined as the ten nucleotides immediately upstream of the initiator or start codon of the open reading frame of a DNA
5 sequence coding for a polypeptide. The initiator or start codon encodes for the AA methionine. The initiator codon is typically ATG, but may also be any functional start codon such as GTG. It is well known in the art that uracil, U, replaces the deoxynucleotide thymine, T, in RNA.

The biological activity of a transcriptional initiator sequence can be determined in
10 a quantitative way by measuring the amount of transcribed gene-product of the open reading frame immediately downstream of the transcriptional initiator sequence and comparing this amount to the amount measured from the same open reading frame controlled by a reference transcriptional initiator sequence. The amount of gene product may be determined by measuring either the amount of mRNA or the amount of
15 polypeptide encoded by the mRNA. Examples of methods known to the skilled person to determine the amount of mRNA include, but are not limited to Northern blot, Quantitative PCR, Real Time PCR, and micro-array analyses. The amount of polypeptide encoded by the open reading frame immediately downstream of the transcriptional initiator sequence can *inter alia* be determined using protein measurement assays known to the skilled
20 person. When the polypeptide encoded by the open reading frame immediately downstream of the transcriptional initiator sequence is an enzyme, the amount of polypeptide can be measured using an activity assay specific for the concerned enzyme. The skilled person will know which assay to select for a specific enzyme. A preferred assay to determine the biological activity of the transcriptional initiator sequence is an
25 activity assay specific for a concerned enzyme.

According to a preferred embodiment, a nucleotide sequence, preferably a nucleotide sequence of the first aspect of the invention, comprises a translational initiator sequence, said translational initiator sequence comprises the nucleic acid sequence as
30 defined by the consensus translational initiator sequence: 5'-mwChkyCAMv-3' (i.e. SEQ ID NO. 16), using ambiguity codes for nucleotides: m (A/C); r (A/G); w (A/T); s (C/G); y (C/T); k (G/T); v (A/C/G); h (A/C/T); d (A/G/T); b (C/G/T); n (A/C/G/T). More preferably, the consensus translational initiator sequence is one selected from the following list: 5'-mwChkyCAAA-3' (i.e. SEQ ID NO. 17); 5'-mwChkyCACA-3' (i.e. SEQ ID NO. 18) or 5'-

mwChkyCAAG-3' (i.e. SEQ ID NO. 19). These more preferred sequences correspond to any one of the following sequences: AACAGCCAAA; AACAGTCAAA; AACATCCAAA; AACATTCAAA; AACCGCCAAA; AACCGTCAAA; AACCTCCAAA; AACCTTCAAA; AACTGCCAAA; AACTGTCAAA; AACTTCCAAA; AACTTTCAAA; ATCAGCCAAA; ATCAGTCAAA; ATCATCCAAA; ATCATTCAAA; ATCCGCCAAA; ATCCGTCAAA; ATCCTCCAAA; ATCCTTCAAA; ATCTGCCAAA; ATCTGTCAAA; ATCTTCCAAA; ATCTTTCAAA; CACAGCCAAA; CACAGTCAAA; CACATCCAAA; CACATTCAAA; CACCGCCAAA; CACCGTCAAA; CACCTCCAAA; CACCTTCAAA; CACTGCCAAA; CACTGTCAAA; CACTTCCAAA; CACTTTCAAA; CTCAGCCAAA; CTCAGTCAAA; CTCATCCAAA; CTCATTCAAA; CTCCGCCAAA; CTCCGTCAAA; CTCCTCCAAA; CTCCTTCAAA; CTCTGCCAAA; CTCTGTCAAA; CTCTTCCAAA; CTCTTTCAAA; AACAGCCACA; AACAGTCAACA; AACATCCACA; AACATTCAACA; AACCGCCACA; AACCGTCAACA; AACCTCCACA; AACCTTCAACA; AACTGCCACA; AACTGTCAACA; AACTTCCACA; AACTTTCAACA; ATCAGCCACA; ATCAGTCAACA; ATCATCCACA; ATCATTCAACA; ATCCGCCACA; ATCCGTCAACA; ATCCTCCACA; ATCCTTCAACA; ATCTGCCACA; ATCTGTCAACA; ATCTTCCACA; ATCTTTCAACA; CACAGCCACA; CACAGTCAACA; CACATCCACA; CACATTCAACA; CACCGCCACA; CACCGTCAACA; CACCTCCACA; CACCTTCAACA; CACTGCCACA; CACTGTCAACA; CACTTCCACA; CACTTTCAACA; CTCAGCCACA; CTCAGTCAACA; CTCATCCACA; CTCATTCAACA; CTCCGCCACA; CTCCGTCAACA; CTCCTCCACA; CTCCTTCAACA; CTCTGCCACA; CTCTGTCAACA; CTCTTCCACA; CTCTTTCAACA; AACAGCCAAG; AACAGTCAAG; AACATCCAAG; AACATTCAAG; AACCGCCAAG; AACCTCCAAG; AACCTTCAAG; AACTGCCAAG; AACTGTCAAG; AACTTCCAAG; AACTTTCAAG; ATCAGCCAAG; ATCAGTCAAG; ATCATCCAAG; ATCATTCAAG; ATCCGCCAAG; ATCCGTCAAG; ATCCTCCAAG; ATCCTTCAAG; ATCTGCCAAG; ATCTGTCAAG; ATCTTCCAAG; ATCTTTCAAG; CACAGCCAAG; CACAGTCAAG; CACATCCAAG; CACATTCAAG; CACCGCCAAG; CACCGTCAAG; CACCTCCAAG; CACCTTCAAG; CACTGCCAAG; CACTGTCAAG; CACTTCCAAG; CACTTTCAAG; CTCAGCCAAG; CTCAGTCAAG; CTCATCCAAG; CTCATTCAAG; CTCCGCCAAG; CTCCGTCAAG; CTCCTCCAAG; CTCCTTCAAG; CTCTGCCAAG; CTCTGTCAAG; CTCTTCCAAG or CTCTTTCAAG.

According to a more preferred embodiment, the translational initiator sequence is 5'-CACCGTCAAA-3' (i.e. SEQ ID NO. 22) or 5'-CGCAGTCAAG-3' (i.e. SEQ ID NO. 23).

The present invention further encompasses isolated translational initiator sequences, variants and subsequences thereof still having the same biological activity as the isolated translational initiator sequence.

The consensus translational initiator sequence of the invention is preferably
5 comprised in a nucleotide sequence of the first aspect of the invention. Alternatively, the consensus translational initiator sequence of the invention may be comprised in any nucleotide sequence comprising a nucleotide coding sequence encoding a compound of interest. The nucleotide coding sequence may be any coding sequence. Preferably, the nucleotide coding sequence is a synonymous coding sequence as defined previously.

10 Furthermore, and according to another aspect of the invention, there is provided a nucleic acid construct or expression vector as defined in the section "Nucleic acid constructs", said nucleic acid construct or expression vector comprising the consensus translational initiator sequence of the invention.

15 The consensus translational initiator sequence of the invention can be used in any filamentous fungal cell for expressing any nucleic acid sequence encoding any compound to be produced in said cell. Filamentous fungal cells are defined in the section "Host cells".

In the present invention, the consensus translational initiator sequence is
20 preferably foreign to the nucleic acid sequence encoding the polypeptide to be produced, but the consensus translational initiator sequence may be native to the fungal host cell.

The skilled person will understand that the invention relates to several distinct embodiments, which can be used separately or in combination:

25 - a synonymous nucleotide coding sequence by using optimal codon frequency and/or modification of control sequences such as:

- a translational termination sequence orientated in 5' towards 3' direction selected from the list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or

30 - a translational initiator coding sequence orientated in 5' towards 3' direction selected from the list of sequences: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCT TCC TTC, and/or

- a translational initiator sequence, said translational initiator sequence comprising the nucleic acid sequence as defined by the consensus translational initiator sequence: 5'-mwChkyCAmv-3', using ambiguity codes for nucleotides: m (A/C); r (A/G); w (A/T); s (C/G); y (C/T); k (G/T); v (A/C/G); h (A/C/T); d (A/G/T); b (C/G/T); n (A/C/G/T),
5 preferably the translational initiator sequence is one selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3', more preferably, the translational initiator sequence is 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.

The skilled person will understand that the invention relates to several distinct
10 embodiments, which can be used separately or in various distinct combinations, several of these combinations are disclosed below.

Preferably, the nucleotide sequence of the invention comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein.

15 According to a more preferred embodiment, the nucleotide sequence of the invention comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein, said synonymous coding sequence being associated with a control sequence comprising one translational
20 termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence of the invention comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein, said synonymous coding sequence being associated with a control sequence comprising the following
25 translational termination sequence 5'-TAAA-3'.

According to an even more preferred embodiment, the nucleotide sequence of the invention comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein, said synonymous coding
30 sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed). More preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein,

said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3'. Even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein, said synonymous coding sequence being associated with the following translational initiator sequence 5'-CGCAGTCAAG-3'. Most preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein, said synonymous coding sequence being associated with the following translational initiator sequence 5'-CACCGTCAAA-3'.

According to a yet even more preferred embodiment, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3' and 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or the following translational termination sequence 5'-TAAA-3'. Even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being

associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being associated with the following translational initiator sequence 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Most preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein; said synonymous coding sequence being associated with the following translational initiator sequence 5'-CACCGTCAAA-3' and/or the following translational termination sequence 5'-TAAA-3'.

According to a most preferred embodiment, the nucleotide sequence of the invention comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3' and 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or the following translational termination sequence 5'-TAAA-3'. Even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list:

5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with a control sequence comprising a translational initiator sequence selected from of the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with the following translational initiator sequence 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Most preferably, the nucleotide sequence comprises a synonymous coding sequence, which has an optimized codon frequency according the invention as disclosed herein and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence being associated with the following translational initiator sequence 5'-CACCGTCAAA-3' and/or the following translational termination sequence 5'-TAAA-3'.

Alternatively and according to another preferred embodiment of the invention, the nucleotide sequence of the invention comprises a coding sequence, said coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed). More preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising a translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3'. Even more preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising the translational initiator sequence 5'-CGCAGTCAAG-3'. Most preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising the translational initiator sequence 5'-CACCGTCAAA-3'.

Alternatively and according to another more preferred embodiment of the invention, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding
5 sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed). More preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said
10 coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3'. Even more preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence
15 comprising the translational initiator sequence 5'-CGCAGTCAAG-3'. Most preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence comprising the translational initiator sequence 5'-CACCGTCAAA-3'.

20

Alternatively and according to another more preferred embodiment of the invention, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising a translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed)
25 and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising a translational initiator sequence selected
30 from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or the following translational termination sequence 5'-TAAA-3'. Even more preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising a translational initiator sequence selected from the following

list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a control sequence comprising a translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a translational initiator sequence 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a translational initiator sequence 5'-CACCGTCAAA-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Most preferably, the nucleotide sequence comprises a coding sequence, said coding sequence being associated with a translational initiator sequence 5'-CACCGTCAAA-3' and/or the following translational termination sequence 5'-TAAA-3'.

Alternatively and according to a most preferred embodiment of the invention, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed) and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence comprising one translational initiator sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier disclosed)

and/or the following translational termination sequence 5'-TAAA-3'. Even more preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence comprising one translational initiator sequence
5 selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being
10 associated with a control sequence comprising a translational initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated
15 with a translational initiator sequence 5'-CGCAGTCAAG-3' and/or one translational termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated
20 with a translational initiator sequence 5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-3'. Most preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a translational initiator sequence 5'- CACCGTCAAA -3' and/or the following translational
25 termination sequence 5'-TAAA-3'.

Alternatively and according to another preferred embodiment of the invention, the nucleotide sequence of the invention comprises a coding sequence, said coding sequence being associated with a control sequence comprising one translational
30 termination sequence orientated in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence of the invention comprises a coding sequence, said coding sequence being associated with the following translational termination sequence 5'-TAAA-3'.

Alternatively and according to another preferred embodiment of the invention, the nucleotide sequence of the invention comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a control sequence comprising one translational termination sequence orientated in 5' towards 3' direction selected from the following list:
5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide sequence comprises a coding sequence and/or comprises the following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being associated with the following translational termination sequence 5'-TAAA-3'.

In addition to the control sequences defined in the first aspect of the invention, other control sequences may be used. Such other control sequence may be an appropriate promoter sequence, a nucleotide sequence, which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences, which mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence, which shows transcriptional activity in the cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the cell.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator, which is functional in the cell, may be used in the present invention.

Preferred terminators for filamentous fungal cells are obtained from the genes encoding *A. oryzae* TAKA amylase, *A. niger* glucoamylase (glaA), *A. nidulans* anthranilate synthase, *A. niger* alpha-glucosidase, trpC gene and *Fusarium oxysporum* trypsin-like protease.

The control sequence may also be a suitable leader sequence, a non-translated region of a mRNA which is important for translation by the cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence, which is functional in the cell, may be used in the present invention.

Preferred leaders for filamentous fungal cells are obtained from the genes encoding *A. oryzae* TAKA amylase and *A. nidulans* triose phosphate isomerase and *A. niger* glaA.

Other control sequences may be isolated from the *Penicillium* IPNS gene, or pcbC gene, the beta tubulin gene. All the control sequences cited in WO 01/21779 are herewith incorporated by reference.

The control sequence may also be a polyadenylation sequence, a sequence
 5 which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence, which is functional in the cell, may be used in the present invention.

Preferred polyadenylation sequences for filamentous fungal cells are obtained
 10 from the genes encoding *A. oryzae* TAKA amylase, *A. niger* glucoamylase, *A. nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-like protease and *A. niger* alpha-glucosidase.

The nucleotide sequence of the invention may be comprised in a nucleic acid construct or expression vector.

15

Nucleic acid constructs

According to a third aspect, the invention relates to a nucleic acid construct or expression vector comprising at least one the nucleotide sequences defined in the former sections:

20 - a synonymous nucleotide coding sequence by using optimal codon frequency and optionally modification of control sequences such as:

- one translational termination sequence orientated in 5' towards 3' direction selected from the following list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or

25 - one translational initiator coding sequence orientated in 5' towards 3' direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCT TCC
 30 TTC, and/or

- a translational initiator sequence, said translational initiator sequence comprising the nucleic acid sequence as defined by the consensus translational initiator sequence: 5'-mwChkyCAmv-3', using ambiguity codes for nucleotides: m (A/C); r (A/G); w (A/T); s (C/G); y (C/T); k (G/T); v (A/C/G); h (A/C/T); d (A/G/T); b (C/G/T); n (A/C/G/T),

preferably the translational initiator sequence is one selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3'. These preferred sequences correspond to any one of the following sequences: AACAGCCAAA; AACAGTCAAA; AACATCCAAA; AACATTCAAA; AACCGCCAAA; AACCGTCAAA; AACCTCCAAA; AACCTTCAAA; AACTGCCAAA; AACTGTCAAA; AACTTCCAAA; AACTTTCAAA; ATCAGCCAAA; ATCAGTCAAA; ATCATCCAAA; ATCATTCAAA; ATCCGCCAAA; ATCCGTCAAA; ATCCTCCAAA; ATCCTTCAAA; ATCTGCCAAA; ATCTGTCAAA; ATCTTCCAAA; ATCTTTCAAA; CACAGCCAAA; CACAGTCAAA; CACATCCAAA; CACATTCAAA; CACCGCCAAA; CACCGTCAAA; CACCTCCAAA; CACCTTCAAA; CACTGCCAAA; CACTGTCAAA; CACTTCCAAA; CACTTTCAAA; CTCAGCCAAA; CTCAGTCAAA; CTCATCCAAA; CTCATTCAAA; CTCCGCCAAA; CTCCGTCAAA; CTCCTCCAAA; CTCCTTCAAA; CTCTGCCAAA; CTCTGTCAAA; CTCTTCCAAA; CTCTTTCAAA; AACAGCCACA; AACAGTCAACA; AACATCCACA; AACATTCAACA; AACCGCCACA; AACCGTCAACA; AACCTCCACA; AACCTTCAACA; AACTGCCACA; AACTGTCAACA; AACTTCCACA; AACTTTCAACA; ATCAGCCACA; ATCAGTCAACA; ATCATCCACA; ATCATTCAACA; ATCCGCCACA; ATCCGTCAACA; ATCCTCCACA; ATCCTTCAACA; ATCTGCCACA; ATCTGTCAACA; ATCTTCCACA; ATCTTTCAACA; CACAGCCACA; CACAGTCAACA; CACATCCACA; CACATTCAACA; CACCGCCACA; CACCGTCAACA; CACCTCCACA; CACCTTCAACA; CACTGCCACA; CACTGTCAACA; CACTTCCACA; CACTTTCAACA; CTCAGCCACA; CTCAGTCAACA; CTCATCCACA; CTCATTCAACA; CTCCGCCACA; CTCCGTCAACA; CTCCTCCACA; CTCCTTCAACA; CTCTGCCACA; CTCTGTCAACA; CTCTTCCACA; CTCTTTCAACA; AACAGCCAAG; AACAGTCAAG; AACATCCAAG; AACATTCAAG; AACCGCCAAG; AACCGTCAAG; AACCTCCAAG; AACCTTCAAG; AACTGCCAAG; AACTGTCAAG; AACTTCCAAG; AACTTTCAAG; ATCAGCCAAG; ATCAGTCAAG; ATCATCCAAG; ATCATTCAAG; ATCCGCCAAG; ATCCGTCAAG; ATCCTCCAAG; ATCCTTCAAG; ATCTGCCAAG; ATCTGTCAAG; ATCTTCCAAG; ATCTTTCAAG; CACAGCCAAG; CACAGTCAAG; CACATCCAAG; CACATTCAAG; CACCGCCAAG; CACCGTCAAG; CACCTCCAAG; CACCTTCAAG; CACTGCCAAG; CACTGTCAAG; CACTTCCAAG; CACTTTCAAG; CTCAGCCAAG; CTCAGTCAAG; CTCATCCAAG; CTCATTCAAG; CTCCGCCAAG; CTCCGTCAAG; CTCCTCCAAG; CTCCTTCAAG; CTCTGCCAAG; CTCTGTCAAG; CTCTTCCAAG or CTCTTTCAAG. More preferably, the translational initiator sequence is 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.

According to another preferred embodiment, the nucleic acid construct or expression vector comprises a translational initiator sequence, said translational initiator sequence comprising the nucleic acid sequence as defined by the consensus translational initiator sequence: 5'-mwChkyCAmv-3', using ambiguity codes for nucleotides: m (A/C); r (A/G); w (A/T); s (C/G); y (C/T); k (G/T); v (A/C/G); h (A/C/T); d (A/G/T); b (C/G/T); n (A/C/G/T), preferably the translational initiator sequence is selected amongst the group consisting of: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3'. These preferred sequences correspond to any one of the following sequences:

AACAGCCAAA; AACAGTCAAA; AACATCCAAA; AACATTCAAA;
AACCGCCAAA; AACCGTCAAA; AACCTCCAAA; AACCTTCAAA; AACTGCCAAA;
AACTGTCAAA; AACTTCCAAA; AACTTTCAAA; ATCAGCCAAA; ATCAGTCAAA;
ATCATCCAAA; ATCATTCAAA; ATCCGCCAAA; ATCCGTCAAA; ATCCTCCAAA;
ATCCTTCAAA; ATCTGCCAAA; ATCTGTCAAA; ATCTTCCAAA; ATCTTTCAAA;
CACAGCCAAA; CACAGTCAAA; CACATCCAAA; CACATTCAAA; CACCGCCAAA;
CACCGTCAAA; CACCTCCAAA; CACCTTCAAA; CACTGCCAAA; CACTGTCAAA;
CACTTCCAAA; CACTTTCAAA; CTCAGCCAAA; CTCAGTCAAA; CTCATCCAAA;
CTCATTCAAA; CTCCGCCAAA; CTCCGTCAAA; CTCCTCCAAA; CTCCTTCAAA;
CTCTGCCAAA; CTCTGTCAAA; CTCTTCCAAA; CTCTTTCAAA; AACAGCCACA;
AACAGTCACA; AACATCCACA; AACATTCAACA; AACCGCCACA; AACCGTCACA;
AACCTCCACA; AACCTTCAACA; AACTGCCACA; AACTGTCAACA; AACTTCCACA;
AACTTTCAACA; ATCAGCCACA; ATCAGTCACA; ATCATCCACA; ATCATTCAACA;
ATCCGCCACA; ATCCGTCAACA; ATCCTCCACA; ATCCTTCAACA; ATCTGCCACA;
ATCTGTCAACA; ATCTTCCACA; ATCTTTCAACA; CACAGCCACA; CACAGTCACA;
CACATCCACA; CACATTCAACA; CACCGCCACA; CACCGTCACA; CACCTCCACA;
CACCTTCAACA; CACTGCCACA; CACTGTCAACA; CACTTCCACA; CACTTTCAACA;
CTCAGCCACA; CTCAGTCACA; CTCATCCACA; CTCATTCAACA; CTCCGCCACA;
CTCCGTCAACA; CTCCTCCACA; CTCCTTCAACA; CTCTGCCACA; CTCTGTCAACA;
CTCTTCCACA; CTCTTTCAACA; AACAGCCAAG; AACAGTCAAG; AACATCCAAG;
AACATTCAAG; AACCGCCAAG; AACCGTCAAG; AACCTCCAAG; AACCTTCAAG;
AACTGCCAAG; AACTGTCAAG; AACTTCCAAG; AACTTTCAAG; ATCAGCCAAG;
ATCAGTCAAG; ATCATCCAAG; ATCATTCAAG; ATCCGCCAAG; ATCCGTCAAG;
ATCCTCCAAG; ATCCTTCAAG; ATCTGCCAAG; ATCTGTCAAG; ATCTTCCAAG;
ATCTTTCAAG; CACAGCCAAG; CACAGTCAAG; CACATCCAAG; CACATTCAAG;
CACCGCCAAG; CACCGTCAAG; CACCTCCAAG; CACCTTCAAG; CACTGCCAAG;

CACTGTCAAG; CACTTCCAAG; CACTTTCAAG; CTCAGCCAAG; CTCAGTCAAG;
CTCATCCAAG; CTCATTCAAG; CTCCGCCAAG; CTCCGTCAAG; CTCCTCCAAG;
CTCCTTCAAG; CTCTGCCAAG; CTCTGTCAAG; CTCTTCCAAG or CTCTTTCAAG.
More preferably, the translational initiator sequence is 5'-CACCGTCAAA-3' or 5'-
5 CGCAGTCAAG-3'.

"Nucleic acid construct " is defined herein as a nucleic acid molecule, either single-or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in
10 a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette or expression vector when the nucleic acid construct contains all the control sequences required for expression of a coding sequence.

15 Manipulation of the nucleotide sequence encoding a polypeptide prior to its insertion into a nucleic acid construct or expression vector may be desirable or necessary depending on the nucleic acid construct or expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

20 The present invention also relates to recombinant expression vectors comprising the nucleotide sequences of the invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the
25 nucleic acid sequence encoding the polypeptide at such sites.

Alternatively, the nucleotide sequence encoding the polypeptide may be expressed by inserting the nucleotide sequence or nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector in such a fashion that the coding sequence is
30 operatively associated with the appropriate control sequences for expression, and optional secretion.

The recombinant expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can confer expression of the nucleic acid sequence encoding the polypeptide. The choice of the

vector will typically depend on the compatibility of the vector with the filamentous fungal cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector, which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. An autonomously maintained cloning vector may comprise the AMA1-sequence (see e.g. Aleksenko and Clutterbuck (1997), Fungal Genet. Biol. 21: 373-397).

Alternatively, the vector may be one which, when introduced into the fungal cell, is integrated into the genome and replicated together with the chromosome (s) into which it has been integrated. The integrative cloning vector may integrate at random or at a predetermined target locus in the chromosomes of the fungal host cell. In a preferred embodiment of the invention, the integrative cloning vector comprises a DNA fragment, which is homologous to a DNA sequence in a predetermined target locus in the genome of the fungal host cell for targeting the integration of the cloning vector to this predetermined locus. In order to promote targeted integration, the cloning vector is preferably linearized prior to transformation of the host cell. Linearization is preferably performed such that at least one but preferably either end of the cloning vector is flanked by sequences homologous to the target locus. The length of the homologous sequences flanking the target locus is preferably at least 30bp, preferably at least 50 bp, preferably at least 0.1kb, even preferably at least 0.2kb, more preferably at least 0.5 kb, even more preferably at least 1 kb, most preferably at least 2 kb. Preferably, the DNA sequence in the cloning vector, which is homologous to the target locus is derived from a highly expressed locus meaning that it is derived from a gene, which is capable of high expression level in the filamentous fungal host cell. A gene capable of high expression level, i.e. a highly expressed gene, is herein defined as a gene whose mRNA can make up at least 0.5% (w/w) of the total cellular mRNA, e.g. under induced conditions, or alternatively, a gene whose gene product can make up at least 1% (w/w) of the total cellular protein, or, in case of a secreted gene product, can be secreted to a level of at least 0.1 g/l (as described in EP 357 127 B1). A number of preferred highly expressed fungal genes are given by way of example: the amylase, glucoamylase, alcohol dehydrogenase, xylanase, glyceraldehyde-phosphate dehydrogenase or cellobiohydrolase (cbh) genes from *Aspergilli* or *Trichoderma*. Most preferred highly expressed genes for these purposes are a glucoamylase gene, preferably an *A. niger*

glucoamylase gene, an *A. oryzae* TAKA-amylase gene, an *A. nidulans* gpdA gene, a *Trichoderma reesei* cbh gene, preferably cbh1. More than one copy of a nucleic acid sequence encoding a polypeptide may be inserted into the host cell to increase production of the gene product. This can be done, preferably by integrating into its genome copies of the DNA sequence, more preferably by targeting the integration of the DNA sequence at one of the highly expressed locus defined in the former paragraph. Alternatively, this can be done by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent. To increase even more the number of copies of the DNA sequence to be over expressed the technique of gene conversion as described in WO98/46772 may be used.

The vector system may be a single vector or plasmid or two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the filamentous fungal cell, or a transposon.

The vectors preferably contain one or more selectable markers, which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. A selectable marker for use in a filamentous fungal cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricinacetyltransferase), bleA (phleomycin binding), hygB (hygromycinphosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenylyltransferase), and trpC (anthranilate synthase), as well as equivalents from other species. Preferred for use in an *Aspergillus* and *Penicillium* cell are the amdS (EP 635574 B1, WO 97/06261) and pyrG genes of *A. nidulans* or *A. oryzae* and the bar gene of *Streptomyces hygrosopicus*. More preferably an amdS gene is used, even more preferably an amdS gene from *A. nidulans* or *A. niger*. A most preferred selection marker gene is the *A. nidulans* amdS coding sequence fused to the *A. nidulans* gpdA promoter (see EP 635574 B1). AmdS genes from other filamentous fungi may also be used (WO 97/06261).

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).

Host cells

According to a fourth aspect, the invention relates to a filamentous fungal host cell. The filamentous fungal host cell of the invention may be any filamentous fungal host cell known to the skilled person.

5 "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a mycelia wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligatory aerobic. Filamentous fungal strains include, but are not limited to, strains of *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*,
10 *Chrysosporium Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, and *Trichoderma*.

Strains of *Aspergillus* and teleomorphs thereof are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC),
15 Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL) *Aspergillus niger* CBS 513.88, *Aspergillus oryzae* ATCC 20423, IFO 4177, ATCC 1011, ATCC 9576,
20 ATCC14488-14491, ATCC 11601, ATCC12892, *P. chrysogenum* CBS 455.95, *Penicillium citrinum* ATCC 38065, *Penicillium chrysogenum* P2, *Acremonium chrysogenum* ATCC 36225 or ATCC 48272, *Trichoderma reesei* ATCC 26921 or ATCC 56765 or ATCC 26921, *Aspergillus sojae* ATCC11906, *Chrysosporium lucknowense* ATCC44006 and derivatives thereof.

25 Preferably, the filamentous fungal host cell of the invention comprises at least one copy of the nucleic acid construct of the third aspect of the invention.

According to a preferred embodiment, the coding and/or control sequences present in the nucleic acid construct are native to the filamentous fungal host cell before
30 modification of the coding and/or control sequences according to the first and second aspect of the invention.

According to another preferred embodiment, the coding and/or control sequences present in the nucleic acid construct are heterologous to the filamentous fungal host cell before modification of the coding and/or control sequences according to the first and
35 second aspect of the invention.

According to a more preferred embodiment, the filamentous fungal host cell of the invention, comprising a given copy number of the nucleic acid construct of the third aspect of the invention is a filamentous fungal cell, wherein the expression of the product encoded by said nucleic acid construct is enhanced as compared to the production of the same product encoded by the corresponding nucleic acid construct comprising the corresponding native nucleotide sequences, said corresponding nucleic acid construct being present in the same copy number in the corresponding filamentous fungal host cell. Preferably, the modification of the nucleotide sequences present in the nucleic acid construct or expression vector of the third aspect of the invention results in an increase by at least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400% more preferably at least 500% of the yield of the compound of interest produced by the filamentous fungal host cell of the invention comprising a given copy number of the nucleic acid construct of the third aspect of the invention, as compared to the production of the corresponding nucleic acid construct comprising the corresponding native nucleotide sequences, said corresponding nucleic acid construct being present in the same copy number in the corresponding filamentous fungal host cell.

The increase in yield of the compound of interest to be produced may be determined by measuring the amount of compound produced by the filamentous fungal host cell of the invention and comparing it to the compound of interest produced by the corresponding filamentous fungal host cell. Determining the yield of compound of interest produced may be performed by measuring *inter alia* the amount of mRNA transcribed from the (synonymous) nucleotide coding sequence, the amount of polypeptide encoded by the mRNA, or the amount of compound (e.g. metabolite) in which' production the polypeptide encoded by the synonymous nucleotide coding sequence is involved with. Examples of methods known to the skilled person to determine the amount of mRNA include, but are not limited to Northern blot, Quantitative PCR, Real Time PCR, and micro-array analyses. The amount of polypeptide can *inter alia* be determined using protein measurement assays known to the skilled person. When the polypeptide is an enzyme, the amount of polypeptide can be measured using an activity assay specific for the concerned enzyme. The skilled person will know which assay to select for a specific enzyme. A preferred assay to determine the yield of the compound of interest to be produced is an activity assay specific for the concerned enzyme.

According to a more preferred embodiment, the host cell of the present invention is a cell belonging to a species selected from the group consisting of an *Aspergillus*, *Penicillium*, *Fusarium*, *Chrysosporum* or *Trichoderma* species, most preferably a species selected from the group consisting of *Aspergillus niger*, *Aspergillus oryzae*,
5 *Aspergillus sojae*, *Aspergillus terreus*, *Chrysosporum lucknowense*, *Trichoderma reesei* or *Penicillium chrysogenum*. A most preferred *Aspergillus niger* host cell is CBS513.88 or derivatives thereof.

The host cell may be a wild type filamentous fungus host cell or a variant, a
10 mutant or a genetically modified filamentous fungus host cell. In a preferred embodiment of the invention the host cell is a protease deficient or protease minus strain. This may be the protease deficient strain *Aspergillus oryzae* JaL 125 having the alkaline protease gene named "alp" deleted (described in WO 97/35956 or EP 429 490), or the tripeptidyl-aminopeptidases (TPAP) deficient strain of *A. niger*, disclosed in WO 96/14404. Further,
15 also host cell with reduced production of the transcriptional activator (prtT) as described in WO 01/68864 is contemplated according to the invention. Another specifically contemplated host strain is the *Aspergillus oryzae* BECh2, where the three TAKA amylase genes present in the parent strain IF04177 has been inactivated. In addition, two proteases, the alkaline protease and neutral metalloprotease 11 have been destroyed by
20 gene disruption. The ability to form the metabolites cyclopiazonic acid and kojic acid has been destroyed by mutation. BECh2 is described in WO 00/39322 and is derived from JaL228 (described in WO 98/12300), which again was a mutant of IF04177 disclosed in US 5,766, 912 as A1560.

Optionally, the filamentous fungal host cell comprises an elevated unfolded protein response (UPR) compared to the wild type cell to enhance production abilities of a
25 polypeptide of interest. UPR may be increased by techniques described in US2004/0186070A1 and/or US2001/0034045A1 and/or WO01/72783A2 and/or WO2005/123763. More specifically, the protein level of HAC1 and/or IRE1 and/or PTC2 has been modulated, and/or the SEC61 protein has been engineered in order to obtain a
30 host cell having an elevated UPR.

Alternatively, or in combination with an elevated UPR, the host cell is genetically modified to obtain a phenotype displaying lower protease expression and/or protease secretion compared to the wild-type cell in order to enhance production abilities of a polypeptide of interest. Such phenotype may be obtained by deletion and/or modification

and/or inactivation of a transcriptional regulator of expression of proteases. Such a transcriptional regulator is e.g. prtT. Lowering expression of proteases by modulation of prtT may be performed by techniques described in US2004/0191864A1.

Alternatively, or in combination with an elevated UPR and/or a phenotype
5 displaying lower protease expression and/or protease secretion, the host cell displays an oxalate deficient phenotype in order to enhance the yield of production of a polypeptide of interest. An oxalate deficient phenotype may be obtained by techniques described in WO2004/070022A2.

Alternatively, or in combination with an elevated UPR and/or a phenotype
10 displaying lower protease expression and/or protease secretion and/or oxalate deficiency, the host cell displays a combination of phenotypic differences compared to the wild cell to enhance the yield of production of the polypeptide of interest. These differences may include, but are not limited to, lowered expression of glucoamylase and/or neutral alpha-amylase A and/or neutral alpha-amylase B, alpha-1, 6transglucosidase, protease, and
15 oxalic acid hydrolase. Said phenotypic differences displayed by the host cell may be obtained by genetic modification according to the techniques described in US2004/0191864A1.

Alternatively, or in combination with phenotypes described here above, the efficiency of targeted integration of a nucleic acid construct into the genome of the host
20 cell by homologous recombination, i.e. integration in a predetermined target locus, is preferably increased by augmented homologous recombination abilities of the host cell. Such phenotype of the cell preferably involves a deficient *hdfA* or *hdfB* gene as described in WO2005/095624. WO2005/095624 discloses a preferred method to obtain a filamentous fungal cell comprising increased efficiency of targeted integration.

25 The introduction of an expression vector or a nucleic acid construct into a filamentous fungal cell may involve a process consisting of protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of *Aspergillus* cells are described in EP 238
30 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81:1470-1474. A suitable method of transforming *Fusarium* species is described by Malardier et al., 1989, Gene 78:147156 or in WO 96/00787. The expression vector or nucleic acid construct that can be used were already described under the corresponding sections.

Producing a compound of interest

The present invention may be used to produce a compound of interest. The compound of interest is preferably a polypeptide. Alternatively, the compound of interest may be a metabolite. In this case, a nucleotide sequence encoding an enzyme involved in the synthesis of the metabolite is modified according to the invention. The term "metabolite" encompasses both primary and secondary metabolites; the metabolite may be any metabolite. A preferred metabolite is citric acid. Another preferred metabolite is a carotenoid. The metabolite may be encoded by one or more genes, such as in a biosynthetic or metabolic pathway. Primary metabolites are products of primary or general metabolism of a cell, which are concerned with energy metabolism, growth, and structure. Secondary metabolites are products of secondary metabolism (see, for example, R. B. Herbert, *The Biosynthesis of Secondary Metabolites*, Chapman and Hall, New York, 1981). The primary metabolite may be, but is not limited to, an amino acid, fatty acid, nucleoside, nucleotide, sugar, triglyceride, or vitamin. The secondary metabolite may be, but is not limited to, an alkaloid, coumarin, flavonoid, polyketide, quinine, steroid, peptide, or terpene. The secondary metabolite may be an antibiotic, antifeedant, attractant, bactericide, fungicide, hormone, insecticide, or rodenticide. Preferred antibiotics are cephalosporins and beta-lactams.

Alternatively, the compound of interest may also be the product of a selectable marker gene. A selectable marker gene is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. In this case, a nucleotide sequence encoding a selectable marker gene product is modified according to the invention. Selectable markers include, but are not limited to, *amdS* (acetamidase), *argB* (ornithinecarbamoyltransferase), *bar* (phosphinothricinacetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), *ble* (phleomycin resistance protein), as well as equivalents thereof.

30

When the compound of interest is a polypeptide, the polypeptide may be any polypeptide whether native or heterologous (or not native) to the cell. As soon as the DNA sequence encoding the polypeptide and the control DNA sequences operatively associated thereto are known, these native or not native DNA sequences are modified

according to the invention (see section DNA sequence), cloned into an appropriate DNA construct or expression vector and transformed into a chosen host. The nucleic acid sequence encoding a heterologous polypeptide may be obtained from any prokaryotic, eukaryotic, plant, or other source. For purposes of the present invention, the term
5 "obtained from" as used herein in connection with a given source shall mean that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.

The term "heterologous polypeptide" is defined herein as a polypeptide, which is
10 not produced by a wild-type cell (not native). The term "polypeptide" is not meant herein to refer to a specific length of the encoded produce and therefore encompasses peptides, oligopeptides and proteins. The polypeptide may also be a recombinant polypeptide, which is a polypeptide native to a cell, which is encoded by an optimized nucleic acid sequence for example and, which additionally may comprise one or more control
15 sequences, foreign to the nucleic acid sequence, which is involved in the production of the polypeptide. The polypeptide may be a wild-type polypeptide or a variant thereof. The polypeptide may also be a hybrid polypeptide, which contains a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides where one or more of the polypeptides may be heterologous to the cell. Polypeptides further
20 include naturally occurring allelic and engineered variations of the above-mentioned polypeptides.

Preferably, the polypeptide is secreted outside the filamentous fungal host cell. In a preferred embodiment, the polypeptide is an antibody or portions thereof, an antigen, a clotting factor, an enzyme, a hormone or a hormone variant, a receptor or portions
25 thereof, a regulatory protein, a structural protein, a reporter, or a transport protein, intracellular protein, protein involved in secretion process, protein involved in folding process, chaperone, peptide amino acid transporter, glycosylation factor, transcription factor. In a preferred embodiment, the polypeptide is secreted into the extracellular environment.

30 In a more preferred embodiment, the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, ligase, catalase, cellulase, chitinase, cutinase, deoxyribonuclease, dextranase, esterase.

In an even more preferred embodiment, the polypeptide is a carbohydrase, e.g., cellulases such as endoglucanases, β -glucanases, cellobiohydrolases or β -

glucosidases, hemicellulases or pectinolytic enzymes such as xylanases, xylosidases, mannanases, galactanases, galactosidases, pectin methyl esterases, pectin lyases, pectate lyases, endo polygalacturonases, exopolygalacturonases, rhamnogalacturonases, arabanases, arabinofuranosidases, arabinoxylan hydrolases, galacturonases, lyases, or amylolytic enzymes; hydrolase, isomerase, or ligase, phosphatases such as phytases, esterases such as lipases, proteolytic enzymes, oxidoreductases such as oxidases, transferases, or isomerases. More preferably, the desired gene encodes a phytase. In an even more preferred embodiment, the polypeptide is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, endo-protease, metallo-protease, serine-protease, catalase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, proteolytic enzyme, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, polyphenoloxidase, ribonuclease, transglutaminase, or glucose oxidase, hexose oxidase, monooxygenase.

In another even more preferred embodiment, the polypeptide is human insulin or an analog thereof, human growth hormone, erythropoietin, tissue plasminogen activator (tPA) or insulinotropin.

The polypeptide may also be an intracellular protein or enzyme such as for example a chaperone, protease or transcription factor. An example of this is described in Appl. Microbiol. Biotechnol. 1998 Oct; 50(4):447-54 ("Analysis of the role of the gene *bipA*, encoding the major endoplasmic reticulum chaperone protein in the secretion of homologous and heterologous proteins in black *Aspergilli*. Punt PJ, van Gemeren IA, Drint-Kuijvenhoven J, Hessing JG, van Muijlwijk-Harteveld GM, Beijersbergen A, Verrips CT, van den Hondel CA). This can be used for example to improve the efficiency of a host cell as protein producer if this polypeptide, such as a chaperone, protease or transcription factor, was known to be a limiting factor in protein production.

Alternatively, the intracellular polypeptide is an enzyme involved in the production of a given secondary metabolite such as a carotenoid or an antibiotic.

The present invention may also be used for the recombinant production of polypeptides, which are native to the cell. The native polypeptide may be recombinantly produced if one modifies the coding and/or control nucleotide sequences as defined in

the corresponding earlier sections. For example, the coding sequence is modified by using the optimized codons frequency as defined earlier to code any amino acid to improve the expression level of the native or naturally occurring nucleotide sequence. Optionally, the synonymous coding sequence obtained may be placed under the control of a different promoter to enhance expression of the polypeptide, to expedite export of a native polypeptide of interest outside the cell by use of a signal sequence of the invention, and to increase the copy number of a gene encoding the polypeptide normally produced by the cell. The present invention also encompasses, within the scope of the term "heterologous polypeptide", such recombinant production of polypeptides native to the cell, to the extent that such expression involves the use of genetic elements not native to the cell, or use of native elements which have been manipulated to function in a manner that do not normally occur in the filamentous fungal cell. The techniques used to isolate or clone a nucleic acid sequence encoding a heterologous polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof.

In the methods of the present invention, heterologous polypeptides may also include a fused or hybrid polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding one polypeptide to a nucleic acid sequence (or a portion thereof) encoding another polypeptide.

Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and expression of the fused polypeptide is under control of the same promoter (s) and terminator. The hybrid polypeptides may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to the mutant fungal cell. An isolated nucleic acid sequence encoding a heterologous polypeptide of interest may be manipulated in a variety of ways to provide for expression of the polypeptide. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, posttranscriptional modification, translation, post-translational modification, and secretion. Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the expression

vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

5 The compound of interest described in the section here above may be produced in a filamentous fungal host cells provided by the invention.

Thus, according to another aspect, the invention relates to methods of producing a compound of interest in a filamentous fungal host cell of the present invention, comprising:

10 (a) cultivating the filamentous fungal host cell as defined in the former section in a nutrient medium suitable for production of the compound of interest; and

(b) recovering the compound of interest from the nutrient medium of the filamentous fungal host cell.

15 The filamentous fungal host cells of the present invention are cultivated in a nutrient medium suitable for production of the compound of interest using methods known in the art. For example, the cells may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the compound of interest to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen
20 sources and inorganic salts, using procedures known in the art (see, e.g., Bennett, J. W. and LaSure, L., eds., *More Gene Manipulations in Fungi*, Academic Press, CA, 1991). Suitable media are available from commercial suppliers or may be prepared using published compositions (e.g., in catalogues of the American Type Culture

25 Collection). If the compound of interest is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the compound of interest is not secreted, it is recovered from cell lysates.

The resulting compound of interest may be isolated by methods known in the art. For example, the polypeptide may be isolated from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray drying,
30 evaporation, or precipitation. The isolated compound of interest may then be further purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing, differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
35

The compound of interest may be detected using methods known in the art that are specific for the polypeptide. These detection methods may include use of specific antibodies, formation of an enzyme product, disappearance of an enzyme substrate, or SDS PAGE. For example, an enzyme assay may be used to determine the activity if the compound of interest is an enzyme. Procedures for determining enzyme activity are known in the art for many enzymes.

In the method of the invention, the yield of the compound of interest produced by the filamentous fungal host of the invention comprising a given copy number of the nucleic acid construct of the third aspect of the invention is preferably increased by at least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400% more preferably at least 500%, as compared to the production of the corresponding nucleic acid construct comprising the corresponding native nucleotide sequences, said corresponding nucleic acid construct being present in the same copy number in the corresponding filamentous fungal host cell. Preferably, the filamentous fungal host cell of the present invention is an *Aspergillus*, *Trichoderma*, *Fusarium*, *Chrysosporum* or *Penicillium* host cell. More preferably the filamentous fungal host cell is an *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus sojae*, *Aspergillus terreus*, *Chrysosporum lucknowense*, *Trichoderma reesei* or *Penicillium chrysogenum* host cell. A most preferred *Aspergillus niger* host cell is CBS513.88 or derivatives thereof.

In another preferred embodiment, the yield of the compound of interest produced by the filamentous fungal host of the invention comprising a given copy number of the nucleic acid construct of the third aspect of the invention, is preferably 0.1 g per liter, 0.2 g, 0.3 g, 0.4 g, more preferably 0.5 g and even most preferably more than 0.5 g per liter of the compound of interest. The production of the compound of interest can be determined by a specific assay. Preferably, the filamentous fungal host cell of the present invention is an *Aspergillus*, *Trichoderma*, *Fusarium*, *Chrysosporum* or *Penicillium* host cell. More preferably the filamentous fungal host cell is an *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus sojae*, *Aspergillus terreus*, *Chrysosporum lucknowense*, *Trichoderma reesei* or *Penicillium chrysogenum* host cell. A most preferred *Aspergillus niger* host cell is CBS513.88 or derivatives thereof.

Alternatively and according to another preferred embodiment, when the polypeptide is an enzyme involved in the production of a given metabolite such as (beta-lactam) antibiotics or carotenoids, the filamentous fungal host cell of the invention is used for the production of a given metabolite.

5

According to a further aspect of the invention, there is provided the use of any one of the nucleotide sequences defined in the corresponding section in a method for producing a compound of interest, the use of a nucleic acid construct or expression vector defined in the corresponding section in a method for producing a compound of interest and the use of any one of the filamentous fungal host cells as defined in the corresponding section in a method for producing a compound of interest.

10

Method for producing a nucleotide sequence; calculation of the optimized codon frequency.

15

According to a further aspect of this invention, there is provided a method for producing the nucleotide sequence of the first aspect of the invention, comprising the steps of:

20

- providing a synonymous nucleotide coding sequence with optimized codon frequency as defined in the first aspect of the invention, and optionally
- operably linking said synonymous nucleotide coding sequence to the control sequences as defined the first aspect of the invention.

25

To provide a synonymous nucleotide coding sequence with optimized coding frequency, the optimized coding frequency can be calculated by the method provided by the invention. This method is outlined below.

For the amino acids, hereafter called as group 1 amino acids (AA), there is only one possibility. Group 1 consists of methionine that is always encoded by ATG and tryptophane that is always encoded by TGG.

30

The amino acids, hereafter called as group 2 AA, are subject to optimization according to the extreme frequency of 0% or 100%, the strategy is clear. All codons for a group 2 AA are specifically changed into the codons listed below. More specifically:

- cysteine is always encoded by TGC;
- phenylalanine by TTC;
- histidine by CAC;

- lysine by AAG,
- asparagine by AAC;
- glutamine by CAG;
- tyrosine by TAC.

5 All other AA, hereafter called group 3 AA, can be encoded by several codons as indicated in Table 1; each codon being present in a preferred codon frequency:

- alanine is encoded by GCT, GCC, GCA, or GCG;
- aspartate by GAT, GAC;
- glutamate by GAA, GAG;
- 10 - glycine by GGT, GGC, GGA, GGG;
- isoleucine by ATT, ATC, ATA;
- leucine by TTA, TTG, CTT, CTC, CTA, CTG;
- proline by CCT, CCC, CCA, CCG;
- arginine by CGT, CGC, CGA, CGG, AGA, AGG;
- 15 - serine by TCT, TCC, TCA, TCG, AGT, AGC;
- threonine by ACT, ACC, ACA, ACG;
- valine by GTT, GTC, GTA, GTG.

The following rules apply for calculation of the optimized codon frequency for group 3 AA in a given coding sequence:

20 For the group 3 AA and their different corresponding codons, the calculation of the optimal occurrence of each possible codon within a given coding sequence is preferably performed according to the following methodology:

- i. sum for each of the respective group 3 AA, the total number of residues encoded in the given sequence,
- 25 ii. for each AA and codon encoding that AA, multiply the total number for that AA by the optimal codon distribution in Table 1, resulting in a raw codon distribution, which generally may contain decimal numbers,
- iii. round off the values of the raw codon distribution (ii), by removing the digits, resulting in a rounded off codon distribution,
- 30 iv. sum for each of the AA, the total number of AA represented in the rounded off codon distribution (iii),
- v. calculate the total missing number of residues for each of the respective AA in the rounded off codon distribution, by subtracting the total number of

- residues encoded in the given sequence (i) with the total number of AA represented in the rounded off codon distribution (iv)
- vi. calculate for each codon, the decimal difference between the raw codon distribution (ii) and the rounded off codon distribution (iii) by subtraction
 - 5 vii. multiply for each codon, the decimal difference (vi) and the optimal codon distribution in table 1, giving a weight value for each codon,
 - viii. for each of the respective AA, select for the amount of missing residues (v), the respective amount of codons that have the highest weight value (vii),
 - 10 ix. the calculation of the final optimal codon distribution within a given sequence encoding a polypeptide is calculated by summing the rounded off codon distribution (iii) and the selected amount of missing residues (viii) for each codon.

15 Subsequently, for codons of which the total number in a given sequence is higher than in the calculated final optimal codon distribution, a selection is made for substitution into a different corresponding codon as calculated. Also for codons that should be increased in frequency, a selection is made from the other different corresponding codon candidates that should be decreased in frequency (see example 1). In another preferred

20 method, one might consider using a computer algorithm for selection and calculation of codon replacements in a given nucleotide sequence. In another preferred embodiment, the selection and calculation of codon replacements may be done according to the calculated codon frequency and criteria for secondary structures and other features like inclusion of certain RNA-tags or restriction sites, and avoiding certain nucleotide

25 sequences. "Secondary structure" refers to regions of a nucleic acid sequence that, when single stranded, have a tendency to form double-stranded hairpin structures or loops. Such structures may impede transcription and translation. In WO 01/55342 possible ways are provided how to evaluate nucleic acids for their likeliness to form secondary structures. Several software programs can predict secondary structures. In a

30 preferred embodiment the secondary structure is determined by the nearest-neighbor method. A description of this method is described by Freier et al (Proc Natl Acad Sci USA 1986, 83, 9373-9377), and uses the energy parameters which refer to RNA:RNA secondary structure. The application of this method can be done in the Clone Manager 7 program (Sci. Ed. Central: Scientific & Educational software, version 7.02).

According to another preferred method, one applies the optimized codon frequency according to Table 1 to a specific part of the coding sequence only. In a more preferred embodiment of the invention, the substitution of codons in a given nucleotide sequence is performed after doing a random selection of candidates for replacement, and a random
5 selection of new corresponding codon candidates, according to the final optimal codon distribution.

According to another preferred method, one applies the calculated optimal codon distribution based on an amino acid sequence only. The amino acid sequence is back-translated into a nucleotide sequence by an appropriate choice of codons according to
10 the calculated optimal codon distribution into a modified coding sequence with optimized codon frequency (example 2). After design of the modified coding sequence, it might be checked for secondary structure features, AT-rich stretches and unwanted restriction sites. In case one observes such aspects, a person skilled in the art knows how to interchange or replace specific codons of the modified coding sequence to circumvent
15 the specific issue without changing the encoded polypeptide. In a preferred embodiment, this can be done by a computer algorithm taking into account specific criteria for secondary structure, avoiding AT-rich regions, avoiding GC-rich regions, introduction of restriction sites, etc. In another embodiment, the back-translation is done by a random choice of position for each codon that needs to be placed in the nucleotide sequence.

To provide the nucleotide sequence with the desired modifications, general molecular biological methods can be applied. These techniques for modifying nucleotide sequences utilizing cloning methods are well known in the art. Such methods include e.g.: random or directed mutagenesis, DNA shuffling methods, DNA reassembly
25 methods, gene synthesis, and other means known to one skilled in the art (see for example Young and Dong, (2004), *Nucleic Acids Research* 32, (7) electronic access <http://nar.oupjournals.org/cgi/reprint/32/7/e59> or Gupta *et al.* (1968), *Proc. Natl. Acad. Sci USA*, 60: 1338-1344; Scarpulla *et al.* (1982), *Anal. Biochem.* 121: 356-365; Stemmer *et al.* (1995), *Gene* 164: 49-53).

According to yet another preferred embodiment, there is provided a method for producing the nucleotide sequence of the second aspect of the invention by providing a nucleotide sequence with a translational initiator sequence according to the second
30

aspect of the invention. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

According to a yet another preferred embodiment, there is provided a method for producing a nucleotide sequence comprising a synonymous nucleotide coding sequence displaying the combined features of the first and second aspect of the invention by:

- providing the synonymous nucleotide coding sequence with optimized codon frequency as defined in the first aspect of the invention using the method described above,
- providing the nucleotide sequence with a translational initiator sequence according to the second aspect of the invention using the method described above, and optionally
- operably linking said synonymous nucleotide coding sequence to the control sequences as defined the first aspect of the invention.

The present invention is further described by the following examples, which should not be construed as limiting the scope of the invention.

Examples

Experimental information

Strains

WT 1: This *A. niger* strain is used as a wild-type strain. This strain is deposited at the CBS Institute under the deposit number CBS 513.88.

WT 2: This *A. niger* strain is a WT 1 strain comprising a deletion of the gene encoding glucoamylase (*glaA*). WT 2 was constructed by using the "MARKER-GENE FREE" approach as described in EP 0 635 574 B1. In this patent it is extensively described how to delete *glaA* specific DNA sequences in the genome of CBS 513.88. The procedure resulted in a MARKER-GENE FREE ?*glaA* recombinant *A. niger* CBS 513.88 strain, possessing finally no foreign DNA sequences at all.

WT 3: This *A. niger* strain is a WT 2 strain comprising a mutation which results in an oxalate deficient *A. niger* strain. WT 3 was constructed by using the method as described in EP1590444. In this patent application, it is extensively described how to screen for an oxalate deficient *A. niger* strain. Strain WT3 was constructed according to the methods of examples 1 and 2 of EP1590444, strain WT 3 is mutant strain 22 of EP1590444 (designated FINALin EP1590444).

***A. niger* shake flask fermentations**

A. niger strains were pre-cultured in 20 ml pre-culture medium as described in the Examples: "*A. niger* shake flask fermentations" section of WO99/32617. After overnight growth, 10 ml of this culture was transferred to fermentation medium 1 (FM1) for alpha-amylase fermentations and fermentation medium 2 (FM2) for phospholipase A1 fermentations. Fermentation is performed in 500 ml flasks with baffle with 100 ml fermentation broth at 34°C and 170 rpm for the number of days indicated, generally as described in WO99/32617.

This FM1 medium contains per liter: 70 g glucose, 25 g Caseinhydrolysate, 12.5 g Yeast extract, 1 g KH₂PO₄, 2 g K₂SO₄, 0.5 g MgSO₄·7H₂O, 0.03 g ZnCl₂, 0.02 g CaCl₂, 0.01 g MnSO₄·4H₂O, 0.3 g FeSO₄·7H₂O, 10 ml Pen-Strep (Invitrogen, cat. nr. 10378-016), adjusted to pH 5.6 with 4 NH₂SO₄.

The FM2 medium contains per liter: 82.5 g Glucose·1H₂O, 25 g Maldex 15 (Boom Meppel, Netherlands), 2 g Citric acid, 4.5 g NaH₂PO₄·1H₂O, 9 g KH₂PO₄, 15 g (NH₄)₂SO₄, 0.02 g ZnCl₂, 0.1 g MnSO₄·1H₂O, 0.015 g CuSO₄·5H₂O, 0.015 g CoCl₂·6H₂O, 1 g MgSO₄·7H₂O, 0.1 g CaCl₂·2H₂O, 0.3 g FeSO₄·7H₂O, 30 g MES (2-[N-Morpholino]ethanesulfonic acid), pH=6.

PLA1 phospholipase activity

To determine phospholipase PLA1 activity (pla1) in *A. niger* culture broth spectrophotometrically, an artificial substrate is used: 1,2-dithiodioctanoyl phosphatidylcholine (diC8, substrate). pla1 hydrolyses the sulphide bond at the A1 position, dissociating thio-octanoic acid. Thio-octanoic acid reacts with 4,4 dithiopyridine (color reagent, 4-DTDP), forming 4-thiopyridone. 4-Thiopyridone is in tautomeric equilibrium with 4-mercaptopyridine, which absorbs radiation having a wavelength of 334 nm. The extinction change at that wavelength is measured. One unit is the amount of

enzyme that liberates of 1 nmol thio-octanoic acid from 1,2-dithiodioctanoyl phosphatidylcholine per minute at 37°C and pH 4.0.

The substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml ethanol and add 264 ml acetate buffer. The acetate buffer comprises 0.1 M Acetate buffer pH 3.85 containing 0.2% Triton-X100. The color reagent is a 11 mM 4,4-dithiodipyridine solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml Eppendorf sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was added.

Fungal alpha-amylase activity

To determine the alpha-amylase activity in *A. niger* culture broth, the Megazyme cereal alpha-amylase kit is used (Megazyme, CERALPHA alpha amylase assay kit, catalogus. ref. K-CERA, year 2000-2001), according protocol of the supplier. The measured activity is based on hydrolysis of non-reducing-endblocked p-nitrophenyl maltoheptaoside in the presence of excess glucoamylase and α -glucosidase. The amount of formed p-nitrophenol is a measure for alpha-amylase activity present in a sample.

Example 1. Construction of an *Aspergillus* expression construct for the pla1 gene encoding *A. oryzae* phospholipase A1 and the amyA gene encoding *A. niger* alpha-amylase

The DNA sequence of the pla1 gene encoding the phospholipase A1 protein was disclosed in JP 1998155493-A/1 and also can be retrieved from EMBL Nucleotide Sequence Database (<http://www.ebi.ac.uk/embl/index.html>) under accession number E16314. The genomic sequence of the native *A. oryzae* pla1 gene is shown as SEQ ID NO: 1. The corresponding coding sequence of pla1 is shown as SEQ ID NO: 2. The translated sequence of SEQ ID NO: 2 is assigned as the SEQ ID NO: 3, representing the *A. oryzae* phospholipase A1.

The DNA sequence of the amyA gene encoding the alpha-amylase protein was disclosed in Curr Genet. 1990 Mar;17(3):203-212 (Cloning, characterization, and expression of two alpha-amylase genes from *Aspergillus niger* var. *awamori* by Korman DR, Bayliss FT, Barnett CC, Carmona CL, Kodama KH, Royer TJ, Thompson SA, Ward M, Wilson LJ, Berka RM) and also can be retrieved from EMBL Nucleotide Sequence Database (<http://www.ebi.ac.uk/embl/index.html>) under accession number AB109452. The genomic

sequence of the native *A. niger amyA* gene is shown as SEQ ID NO. 28. The corresponding coding or cDNA sequence of *amyA* is shown as SEQ ID NO. 29. The translated sequence of SEQ ID NO. 29 is assigned as the SEQ ID NO. 30, representing the *A. niger* alpha-amylase protein.

5

For expression analysis in *Aspergillus* species of pla1 constructs, a fusion of the genomic pla1 gene and the *A. niger* glucoamylase promoter was made at the translation start site accompanied by the introduction of cloning sites. To do so, a PCR was performed for amplification of the genomic pla1 gene using the oligonucleotides identified as SEQ ID NO 4 and SEQ ID NO 5 and the pla1 gene construct cloned in pGBFIN11, described in WO 04/070022, as template, generating a 1.1 kb fragment identified as fragment A. Additionally, a SnaBI cloning site was introduced. A second PCR was performed using the oligonucleotides identified as SEQ ID NO 6 and SEQ ID NO 7 and the pGBFIN-23 vector (described in WO99/32617) as template, generating a 0.4 kb glaA promoter fragment identified as fragment B. Both resulting fragments, A and B, were fused by sequence overlap extension (SOE-PCR, as described in Gene. 1989 Apr 15;77(1):51-9. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR "Site-directed mutagenesis by overlap extension using the polymerase chain reaction") using PCR, oligonucleotides identified as SEQ ID NO 5 and SEQ ID NO 6 and fragments A and B described above; generating a 1.4 kb fragment C. This fragment C, comprising the genomic pla1 gene and part of the glaA promoter was digested with SfiI and SnaBI and introduced in a SfiI and NruI digested pGBFIN-30 vector (Figure 1), generating pGBFINPLA-1a (Fig. 2). The sequence of the introduced and digested PCR fragment C was confirmed by sequence analysis and its sequence is given in SEQ ID NO 8.

For expression analysis in *Aspergillus* species of *A. niger amyA* constructs, a fragment containing the genomic *amyA* promoter and the *amyA* cDNA sequence was amplified and fused using PCR in a similar strategy as described above. Appropriate restriction sites were introduced at both ends to allow cloning in an expression vector. At the 5'-end an *Xho*I site was introduced and at the 3'-end a *Pac*I site. This fragment comprising the alpha-amylase promoter and cDNA sequence was digested with *Xho*I and *Pac*I and introduced in an *Xho*I and *Pac*I digested pGBFIN-12 vector (construction and layout described in WO99/32617), generating pGBFINFUA-1 (Fig. 4). The sequence of the introduced PCR fragment was confirmed by sequence analysis and its sequence is presented in SEQ ID NO. 31.

30

Example 2: Use of a method of the invention for construction of improved DNA sequences for improving production of the phospholipase A1 enzyme of *Aspergillus oryzae* in *A. niger*.

2.1. Improvement of the codon frequency or codon usage for the *A. oryzae* phospholipase A1 coding sequence for expression in *A. niger*

The method of the invention was below applied to the improvement of codon use of the PLA1 gene of *A. oryzae*. This method can be applied the same way for the improvement of codon use of any nucleotide sequence. The nucleotide coding sequence of pla1 is shown as SEQ ID NO:2.

The codon use of the native *A. oryzae* gene encoding PLA1 and the synthetic optimized variant are given in Table 2 below. For the native and optimized synthetic pla1 gene, the exact numbers for each codon are given as well as the distribution per amino acid. Additionally, the third column provides the proposed optimal distribution, which is the target for optimization.

For the group 1 amino acids, there is only one possibility. Group 1 consists of methionine that is always encoded by ATG and tryptophane that is always encoded by TGG.

The group 2 amino acids are subject to optimization according to the extreme frequency of 0% or 100%, the strategy is clear. All codons for a group 2 AA are specifically changed into the optimal variant of the two possible codons. More specifically for cysteine, a codon, TGT is replaced by TGC; for phenylalanine, TTT by TTC; for histidine, CAT by CAC; for lysine, AAA by AAG, for asparagine, AAT by AAC; for glutamine, CAA by CAG; for tyrosine, TAT by TAC.

The group 3 amino acids can be encoded by several codons as indicated in Table 1; each codon being present in a preferred codon frequency: for alanine GCT, GCC, GCA, GCG; for aspartate, GAT, GAC; for glutamate, GAA, GAG; for glycine, GGT, GGC, GGA, GGG; for isoleucine, ATT, ATC, ATA; for leucine, TTA, TTG, CTT, CTC, CTA, CTG;

for proline, CCT, CCC, CCA, CCG; for arginine, CGT, CGC, CGA, CGG, AGA, AGG; for serine, TCT, TCC, TCA, TCG, AGT, AGC; for threonine, ACT, ACC, ACA, ACG; for valine, GTT, GTC, GTA, GTG, are optimized according the following methodology:

- 5 For the group 3 amino acids (AA) and their encoding codons, the calculation of the optimal occurrence of each possible codon within a given coding sequence is performed according to the following methodology:
 - i. sum for each of the respective group 3 AA, the total number of residues encoded in the given sequence, see column A1 (Table 3),
 - 10 ii. for each AA and codon encoding that AA, multiply the total number for that AA by the optimal codon distribution in Table 1, resulting in a raw codon distribution, which generally may contain decimal numbers, see column A2 (Table 4),
 - iii. round off the values of the raw codon distribution (ii), by removing the digits, resulting in a rounded off codon distribution, see column A3 (Table 4),
 - 15 iv. sum for each of the AA, the total number of AA represented in the rounded off codon distribution (iii), see column A4 (Table 3),
 - v. calculate the total missing number of residues for each of the respective AA in the rounded off codon distribution, by subtracting the total number of residues encoded in the given sequence (i) with the total number of AA represented in the rounded off codon distribution (iv), see column A5 (Table 3),
 - 20 vi. calculate for each codon, the decimal difference between the raw codon distribution (ii) and the rounded off codon distribution (iii) by subtraction, see column A6 (Table 4),
 - vii. multiply for each codon, the decimal difference (vi) and the optimal codon distribution in table 1, giving a weight value for each codon, see column A7 (Table 4),
 - 25 viii. for each of the respective AA, select for the amount of missing residues (v), the respective amount of codons that have the highest weight value (vii), see column A8 (Table 4),
 - 30 ix. the calculation of the final optimal codon distribution within a given sequence encoding a polypeptide is calculated by summing the rounded off codon distribution (iii) and the selected amount of missing residues (viii) for each codon, see column A9 (Table 4).

Table 2 Codon optimization for PLA1.

AA	Codon	Optimal codon distribution [%]	PLA1 w.t. [# codons]	PLA1 w.t. [% codons / AA]	PLA1 optimized [# codons]	PLA1 optimized [% codons / AA]
A	Ala_GCT	38	10	28.6	14	40.0
	Ala_GCC	51	12	34.3	18	51.4
	Ala_GCA	0	9	25.7	0	0.0
	Ala_GCG	11	4	11.4	3	8.6
C	Cys_TGT	0	4	66.7	0	0.0
	Cys_TGC	100	2	33.3	6	100.0
D	Asp_GAT	36	14	73.7	7	36.8
	Asp_GAC	64	5	26.3	12	63.2
E	Glu_GAA	26	7	46.7	4	26.7
	Glu_GAG	74	8	53.3	11	73.3
F	Phe_TTT	0	5	55.6	0	0.0
	Phe_TTC	100	4	44.4	9	100.0
G	Gly_GGT	49	6	26.1	12	52.2
	Gly_GGC	35	7	30.4	8	34.8
	Gly_GGA	16	5	21.7	3	13.0
	Gly_GGG	0	5	21.7	0	0.0
H	His_CAT	0	4	50.0	0	0.0
	His_CAC	100	4	50.0	8	100.0
I	Ile_ATT	27	3	33.3	2	22.2
	Ile_ATC	73	6	66.7	7	77.8
	Ile_ATA	0	0	0.0	0	0.0
K	Lys_AAA	0	2	33.3	0	0.0
	Lys_AAG	100	4	66.7	6	100.0
L	Leu_TTA	0	1	2.9	0	0.0
	Leu_TTG	13	9	26.5	4	11.8

	Leu_CTT	17	2	5.9	6	17.6
	Leu_CTC	38	8	23.5	13	38.2
	Leu_CTA	0	2	5.9	0	0.0
	Leu_CTG	32	12	35.3	11	32.4
M	Met_ATG	100	1	100.0	1	100.0
N	Asn_AAT	0	5	27.8	0	0.0
	Asn_AAC	100	13	72.2	18	100.0
P	Pro_CCT	36	3	37.5	3	37.5
	Pro_CCC	64	2	25.0	5	62.5
	Pro_CCA	0	2	25.0	0	0.0
	Pro_CCG	0	1	12.5	0	0.0
Q	Gln_CAA	0	3	60.0	0	0.0
	Gln_CAG	100	2	40.0	5	100.0
R	Arg_CGT	49	0	0.0	4	50.0
	Arg_CGC	51	2	25.0	4	50.0
	Arg_CGA	0	2	25.0	0	0.0
	Arg_CGG	0	3	37.5	0	0.0
	Arg_AGA	0	1	12.5	0	0.0
	Arg_AGG	0	0	0.0	0	0.0
S	Ser_TCT	21	5	15.2	7	21.2
	Ser_TCC	44	7	21.2	15	45.5
	Ser_TCA	0	5	15.2	0	0.0
	Ser_TCG	14	2	6.1	4	12.1
	Ser_AGT	0	4	12.1	0	0.0
	Ser_AGC	21	10	30.3	7	21.2
T	Thr_ACT	30	7	29.2	7	29.2
	Thr_ACC	70	8	33.3	17	70.8
	Thr_ACA	0	2	8.3	0	0.0
	Thr_ACG	0	7	29.2	0	0.0
V	Val_GTT	27	5	33.3	4	26.7
	Val_GTC	54	4	26.7	8	53.3

Val_GTA	0	1	6.7	0	0.0
Val_GTG	19	5	33.3	3	20.0
W Trp_TGG	100	4	100.0	4	100.0
Y Tyr_TAT	0	6	40.0	0	0.0
Tyr_TAC	100	9	60.0	15	100.0

Table 3

AA(i)	i	A1	A4	A5
Ala	1	35	33	2
Asp	2	19	18	1
Glu	3	15	14	1
Gly	4	23	22	1
Ile	5	9	8	1
Leu	6	34	31	3
Pro	7	8	7	1
Arg	8	8	7	1
Ser	9	33	30	3
Thr	10	24	23	1
Val	11	15	14	1

5 Table 4

Codon	A2	A3	A6	A7	A8	A9
Ala_GCT	13.3	13	0.3	0.114	1	14
Ala_GCC	17.85	17	0.85	0.434	1	18
Ala_GCA	0	0	0	0.000	0	0
Ala_GCG	3.85	3	0.85	0.094	0	3
Asp_GAT	6.84	6	0.84	0.302	1	7
Asp_GAC	12.16	12	0.16	0.102	0	12
Glu_GAA	3.9	3	0.9	0.234	1	4
Glu_GAG	11.1	11	0.1	0.074	0	11
Gly_GGT	11.27	11	0.27	0.132	1	12

Gly_GGC	8.05	8	0.05	0.018	0	8
Gly_GGA	3.68	3	0.68	0.109	0	3
Gly_GGG	0	0	0	0.000	0	0
Ile_ATT	2.43	2	0.43	0.116	0	2
Ile_ATC	6.57	6	0.57	0.416	1	7
Ile_ATA	0	0	0	0.000	0	0
Leu_TTA	0	0	0	0.000	0	0
Leu_TTG	4.42	4	0.42	0.055	0	4
Leu_CTT	5.78	5	0.78	0.133	1	6
Leu_CTC	12.92	12	0.92	0.350	1	13
Leu_CTA	0	0	0	0.000	0	0
Leu_CTG	10.88	10	0.88	0.282	1	11
Pro_CCT	2.88	2	0.88	0.317	1	3
Pro_CCC	5.12	5	0.12	0.077	0	5
Pro_CCA	0	0	0	0.000	0	0
Pro_CCG	0	0	0	0.000	0	0
Arg_CGT	3.92	3	0.92	0.451	1	4
Arg_CGC	4.08	4	0.08	0.041	0	4
Arg_CGA	0	0	0	0.000	0	0
Arg_CGG	0	0	0	0.000	0	0
Arg_AGA	0	0	0	0.000	0	0
Arg_AGG	0	0	0	0.000	0	0
Ser_TCT	6.93	6	0.93	0.195	1	7
Ser_TCC	14.52	14	0.52	0.229	1	15
Ser_TCA	0	0	0	0.000	0	0
Ser_TCG	4.62	4	0.62	0.087	0	4
Ser_AGT	0	0	0	0.000	0	0
Ser_AGC	6.93	6	0.93	0.195	1	7
Thr_ACT	7.2	7	0.2	0.060	0	7
Thr_ACC	16.8	16	0.8	0.560	1	17
Thr_ACA	0	0	0	0.000	0	0
Thr_ACG	0	0	0	0.000	0	0
Val_GTT	4.05	4	0.05	0.014	0	4

Val_GTC	8.1	8	0.1	0.054	0	8
Val_GTA	0	0	0	0.000	0	0
Val_GTG	2.85	2	0.85	0.162	1	3

Subsequently, for codons of which the total number in the *pla1* coding sequence was higher than the calculated final codon distribution, a random selection was made for substitution into a different corresponding codon as calculated. Also for codons that should be increased in the *pla1* coding sequence, a random selection was made from the other different corresponding codon candidates that should be decreased in frequency.

This resulted in a modified coding sequence (or synonymous coding sequence or optimized synthetic sequence) as depicted in Table 2. The optimized synthetic *pla1* sequence, resulting from the process described above, is shown in Figure 6. Here an alignment of the modified coding sequence of the invention with the native and genomic *pla1* sequence can be found. In this modified coding sequence, the three introns of the native sequence were placed at their original position (as indicated in SEQ ID NO 1), resulting in the optimized synthetic sequence as shown in the SEQ ID NO 11. Secondary structures in the modified coding sequence were checked using the Clone Manager 7 program (Sci. Ed. Central: Scientific & Educational software, version 7.02) for possible occurrence of harmful secondary structures.

2.2: Choice of a modified translational termination sequence

The native *pla1* gene encoding *A. oryzae* phospholipase A1 contains a 'TAG' stop codon followed by TACGTA of the introduced *Sna*BI restriction site. In a number of synthetic constructs, the 5'-TAGT-3' translational termination sequence is replaced by TAAA followed by the same TACGTA of the *Sna*BI restriction site. This replacement has been done in the sequences of SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 35. As a result of this, the expression constructs pGBFINPLA-1d, pGBFINPLA-1e, pGBFINPLA-1f, pGBFINPLA-1g and pGBFINPLA-1h have a modified translational termination sequence according to the invention.

2.3: Choice of a modified translational initiation sequences

The strong *glaA* promotor is applied for over-expression of enzymes in *A. niger* using the pGBFIN expression constructs. The translational initiation sequence including ATG start codon of *PglaA* is 5'-CACCTCAGCA ATG-3'. The translational initiation sequence of *PglaA* has been modified into 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.

5 This results in a glucoamylase promoter sequence downstream of the *EcoRI* site as can be identified in SEQ ID NO 25 and 26, respectively. This replacement was performed in the sequences of SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 13 and SEQ ID NO. 14. As a result of this, the expression constructs pGBFINPLA-1b, pGBFINPLA-1c, pGBFINPLA-1e, pGBFINPLA-1f and pGBFINPLA-1g have a modified

10 translational initiation sequence according to the invention. The translational initiator sequence as described in US 6,461,837 B1 has been tested in the sequence of SEQ ID NO. 35, resulting in the expression constructs pGBFINPLA-1h.

2.4: Choice of modified translational initiation coding sequence

15 Modification of the translational initiation coding sequence can be combined with the codon optimization and/or improvement of the translational initiation coding sequence. Substitution of the second codon in the coding sequence is clear because only one codon is optimal, i.e., the codon is replaced by GCT coding alanine. The third codon has 4 options: TCC; CCC; ACC; GCC, encoding serine, proline, threonine, and arginine,

20 respectively. TCC was selected. The fourth codon can either be TTC for phenylalanine, TTC for serine, CTC for leucine, or CCC for proline. TTC was selected. This leads to 5'-ATGGCTTCCTTC-3' as modified translational initiation coding sequence including start codon. This results in a glucoamylase promoter sequence downstream of the *EcoRI* site and with translational initiation coding sequence as can be identified in SEQ ID NO 27.

25 This modified sequence is used in SEQ ID NO. 14. As a result of this, the expression construct pGBFINPLA-1g has a modified translational initiation coding sequence according to the invention.

2.5: Combination of at least one of the modifications made in 2.1 to 2.4

30 Expression of the nucleotide sequence coding for the polypeptide to be produced may be improved by optimizing the codon usage, and/or the consensus translational initiator coding sequence and/or control DNA sequences comprising a consensus translational initiator sequence and/or optimal translational termination sequence. A

series of 8 constructs (Table 5) was analysed to test a number of embodiments of the invention.

Table 5: Several improved expression constructs using at least one of the modified sequences. Translational initiator sequence variant 1: CACCGTCAAA; variant 2: CGCAGTCAAG.

SEQ ID NO	Translational initiation sequence	Translational initiation coding sequence	Codon usage	Translation termination sequence
8	w.t.	w.t.	w.t.	w.t.
9	variant 1	w.t.	w.t.	w.t.
10	variant 2	w.t.	w.t.	w.t.
11	w.t.	w.t.	modified	w.t.
12	variant 1	w.t.	modified	Modified (TAA ATA)
13	variant 2	w.t.	modified	Modified (TAA ATA)
14	variant 1	Optimized (ATGGCTTCCTTC)	modified	Modified (TAA ATA)
35	US 6,461,837 B1	w.t.	modified	Modified (TAA ATA)

5

Example 3: Use of a method of the invention for construction of improved DNA sequences for improving production of the alpha-amylase enzyme in *A. niger*.

10 **3.1. Improvement of the codon frequency or codon usage for the alpha-amylase coding sequence *amyA* for expression in *A. niger***

The method of the invention is below applied to the improvement of codon use of the *amyA* gene of *A. niger*. This method can be applied the same way for the improvement of codon use of any nucleotide sequence. The nucleotide coding sequence of the native *amyA* is shown as SEQ ID NO. 29.

15

- x. The codon use of the native *amyA* gene of *A. niger* and the synthetic optimized variant are given in Table 6 below. For the native and optimized synthetic *amyA* gene, the exact numbers for each codon are given as well as the distribution per amino acid. Additionally, the third column provides the proposed optimal distribution, which is the target for optimization.

20

Table 6 Codon optimization for amyA.

AA	Codon	Optimal codon distribution [%]	amyA w.t. [# codons]	amyA w.t. [% codons / AA]	amyA optimized [# codons]	amyA optimized [% codons / AA]
A	Ala_GCT	38	5	11.9	16	38.1
	Ala_GCC	51	15	35.7	21	50.0
	Ala_GCA	0	12	28.6	0	0.0
	Ala_GCG	11	10	23.8	5	11.9
C	Cys_TGT	0	7	77.8	0	0.0
	Cys_TGC	100	2	22.2	9	100.0
D	Asp_GAT	36	20	47.6	15	35.7
	Asp_GAC	64	22	52.4	27	64.3
E	Glu_GAA	26	5	41.7	3	25.0
	Glu_GAG	74	7	58.3	9	75.0
F	Phe_TTT	0	3	20.0	0	0.0
	Phe_TTC	100	12	80.0	15	100.0
G	Gly_GGT	49	10	23.3	21	48.8
	Gly_GGC	35	18	41.9	15	34.9
	Gly_GGA	16	10	23.3	7	16.3
	Gly_GGG	0	5	11.6	0	0.0
H	His_CAT	0	3	42.9	0	0.0
	His_CAC	100	4	57.1	7	100.0
I	Ile_ATT	27	7	25.0	7	25.0
	Ile_ATC	73	19	67.9	21	75.0
	Ile_ATA	0	2	7.1	0	0.0
K	Lys_AAA	0	7	35.0	0	0.0
	Lys_AAG	100	13	65.0	20	100.0
L	Leu_TTA	0	1	2.7	0	0.0

	Leu_TTG	13	10	27.0	5	13.5
	Leu_CTT	17	4	10.8	6	16.2
	Leu_CTC	38	13	35.1	14	37.8
	Leu_CTA	0	3	8.1	0	0.0
	Leu_CTG	32	6	16.2	12	32.4
M	Met_ATG	100	10	100.0	10	100.0
N	Asn_AAT	0	3	11.5	0	0.0
	Asn_AAC	100	23	88.5	26	100.0
P	Pro_CCT	36	6	27.3	8	36.4
	Pro_CCC	64	8	36.4	14	63.6
	Pro_CCA	0	3	13.6	0	0.0
	Pro_CCG	0	5	22.7	0	0.0
Q	Gln_CAA	0	5	25.0	0	0.0
	Gln_CAG	100	15	75.0	20	100.0
R	Arg_CGT	49	1	10.0	5	50.0
	Arg_CGC	51	2	20.0	5	50.0
	Arg_CGA	0	2	20.0	0	0.0
	Arg_CGG	0	2	20.0	0	0.0
	Arg_AGA	0	0	0.0	0	0.0
	Arg_AGG	0	3	8.1	0	0.0
S	Ser_TCT	21	4	10.8	8	21.6
	Ser_TCC	44	9	24.3	16	43.2
	Ser_TCA	0	4	10.8	0	0.0
	Ser_TCG	14	10	27.0	5	13.5
	Ser_AGT	0	4	10.8	0	0.0
	Ser_AGC	21	6	16.2	8	21.6
T	Thr_ACT	30	9	22.5	12	30.0
	Thr_ACC	70	13	32.5	28	70.0
	Thr_ACA	0	10	25.0	0	0.0
	Thr_ACG	0	8	20.0	0	0.0
V	Val_GTT	27	5	16.1	8	25.8

	Val_GTC	54	12	38.7	17	54.8
	Val_GTA	0	4	12.9	0	0.0
	Val_GTG	19	10	32.3	6	19.4
W	Trp_TGG	100	12	100.0	12	100.0
Y	Tyr_TAT	0	11	31.4	0	0.0
	Tyr_TAC	100	24	68.6	35	100.0

Subsequently, a completely new nucleotide coding sequence is created by random distribution of the proposed number of synonymous codons (Table 6) for each amino acid in the original amyA peptide.

5

The native *amyA* gene contains a 'TGA' stop codon. In all *amyA* constructs made, the 5'-TGA-3' translational termination sequence was replaced by 5'-TAAA-3' followed by the 5'-TTAATTAA-3' of the *PacI* restriction site.

This resulted in a modified coding sequence (or synonymous coding sequence or optimized synthetic sequence) as depicted in Table 6. The optimized synthetic *amyA* sequence, resulting from the process described above, is indicated in SEQ ID NO 32. Secondary structures in the modified coding sequence was checked using the Clone Manager 7 program (Sci. Ed. Central: Scientific & Educational software, version 7.02) for possible occurrence of harmful secondary structures.

15

3.2: Choice of a modified translational initiation sequences

In this example, the strong *amyA* promotor is applied for over-expression of the alpha amylase enzyme in *A. niger* using pGBFIN-based expression constructs. The translational initiation sequence including ATG start codon of PamyA is 5'-GGCATTTATG ATG-3' or 5'-GAAGGCATTT ATG-3', dependent on which ATG is selected as start codon. The translational initiation sequence of PamyA has been modified into 5'-CACCGTCAAA ATG-3'. This replacement has been done in the sequences of SEQ ID NO. 33 and SEQ ID NO. 34. As a result of this, the expression constructs pGBFINFUA-2 and pGBFINFUA-3, have a modified translational initiation sequence according to the invention.

25

3.3: Combination of at least one of the modifications made in 3.1 and 3.2

Expression of the sequence coding for the polypeptide to be produced may be improved by optimizing the codon usage and/or control DNA sequences comprising a

consensus translational initiator sequence and/or optimal translational termination sequence. A series of 3 constructs (Table 7) was constructed to test a number of embodiments of the invention.

- 5 Table 7: Overview of improved expression constructs using at least one of the modified sequences.

SEQ ID NO	Translational initiation sequence	Codon usage	Translation termination sequence
31	w.t.	w.t.	Modified (TAA ATTAA)
33	variant 1 (CACCGTCAAA)	w.t.	Modified (TAA ATTAA)
34	variant 1 (CACCGTCAAA)	modified	Modified (TAA ATTAA)

10 **Example 4. Construction of modified expression vectors and testing them in *A. niger***

4.1. Construction of modified *pla1* expression vectors expressing *A. oryzae* phospholipase A1 according example 2.1 – 2.5

15 The DNA sequence of the cloned *Eco*RI - *Sna*BI fragment of pGBFINPLA-1a is shown as SEQ ID NO 8. The DNA sequences of *Eco*RI fragments comprising variants for the translational initiation sequence of the glucoamylase promoter are shown as SEQ ID NO 9 and SEQ ID NO 10. These modified gene fragments were completely synthesized and the sequence was confirmed by sequence analysis.

20

For cloning these modified sequence variants in an expression vector, all synthetic gene fragments were digested with *Eco*RI and introduced in the large fragment of an *Eco*RI digested pGBFINPLA-1a vector (Figure 2), generating variant expression vectors of pGBFINPLA-1a. After checking for the proper orientation of the *Eco*RI fragment, the variant expression constructs were named pGBFINPLA1b and pGBFINPLA-1c as described below in Table 8. Figure 3 is also providing a representative map for plasmid pGBFINPLA-1b and pGBFINPLA-1c.

25 The DNA sequence of 5 other synthetic sequence variants comprising part of the glucoamylase promoter, the *pla1* signal sequence, the mature peptide of phospholipase A1 and the translational termination sequence around the stop codon are shown as SEQ

30

ID NO 11 until SEQ ID NO 14 and SEQ ID NO 35. These 5 modified gene fragments were completely synthesized by design and synthesis of overlapping polynucleotides and subsequent assembly of the double-stranded sequence from a number of overlapping polynucleotides. The sequence was confirmed by sequence analysis.

5 For cloning these modified sequence variants in an expression vector, all synthetic gene fragments were digested with EcoRI and SnaBI and introduced in the large fragment of an EcoRI and NruI digested pGBFINPLA-1a vector (Figure 2), generating variant expression vectors pGBFINPLA-1d until pGBFINPLA-1h as described below in Table 8. A representative map for the plasmids pGBFINPLA-1d until
10 pGBFINPLA-1h is provided in figure 3.

Table 8: Modified expression constructs for pla1 expression in *A. niger*

Plasmid name	SEQ ID NO	Translation start region	Codon	Translation stop
PGBFINPLA-1a	8	CACCTCAGCA ATG TTT AGT CTC	w.t	TAG TAC
PGBFINPLA-1b	9	CACCGTCAAA ATG TTT AGT CTC	w.t	TAG TAC
PGBFINPLA-1c	10	CGCAGTCAAG ATG TTT AGT CTC	w.t	TAG TAC
PGBFINPLA-1d	11	CACCTCAGCA ATG TTC TCT CTC	modified	Modified (TAA ATA)
PGBFINPLA-1e	12	CACCGTCAAA ATG TTC TCT CTC	modified	Modified (TAA ATA)
PGBFINPLA-1f	13	CGCAGTCAAG ATG TTC TCT CTC	modified	Modified (TAA ATA)
PGBFINPLA-1g	14	CACCGTCAAA ATG GCT TCC TTC	modified	Modified (TAA ATA)
pGBFINPLA-1h	35	CTCCTTCACC ATG TTC TCT CTC	modified	Modified (TAA ATA)

The translated sequences of the pla1 coding sequences of plasmid pGBFINPLA-1a until pGBFINPLA-1f and pGBFINPLA-1h are according the amino acid sequence as
15 identified in SEQ ID NO: 3, representing the wild-type *A. oryzae* phospholipase A1. The translated sequence of the pla1 coding sequence of plasmid pGBFINPLA-1g is according the amino acid sequence as identified in SEQ ID NO: 15, representing an *A. oryzae* phospholipase A1 with a modified signal sequence.

4.2. Construction of modified *amyA* expression vectors expressing *A. niger* alpha-amylase according example 3.1 – 3.3

The DNA sequence of the *Xho*I - *Pac*I fragment of pGBFINFUA-1 (Figure 4) is shown as SEQ ID NO 31 and comprises the wild-type *amyA* promoter and wild-type
 5 *amyA* cDNA sequence with a modified translation stop sequence (TAAA). The DNA sequence comprising a variant for the translational initiation sequence of the alpha-amylase promoter is shown as SEQ ID NO 33. The DNA sequence comprising a variant of the translational initiation sequence of the alpha-amylase promoter combined with a codon optimized coding sequence for alpha-amylase encoding *amyA* gene is shown as
 10 SEQ ID NO 34. These modified gene fragments were completely synthesized *in vitro* and the sequence was confirmed by sequence analysis.

For cloning these modified sequence variants in an expression vector, all synthetic gene fragments were digested with *Xho*I and *Pac*I and introduced in the large
 15 fragment of an *Xho*I and *Pac*I digested pGBFINFUA-1 vector (Figure 4), generating variant expression vectors. After checking the integration of the correct fragment, the variant expression constructs were named pGBFINFUA-2 and pGBFINFUA-3 as described below in Table 9.

20 Table 9: Modified expression constructs for alpha-amylase expression in *A. niger*

Plasmid name	SEQ ID NO	Translation start region	Codon	Translation stop
pGBFINFUA-1	31	Wild type (GAAGGCATTT ATG)	w.t	Modified (TAA ATA)
pGBFINFUA-2	33	Modified (CACCGTCAAA ATG)	w.t	Modified (TAA ATA)
pGBFINFUA-3	34	Modified (CACCGTCAAA ATG)	Modified	Modified (TAA ATA)

The translated sequences of the *amyA* coding sequences of plasmid pGBFINFUA-1 to pGBFINFUA-3 are according to the amino acid sequence as depicted in
 25 SEQ ID NO: 30, representing the wild-type *A. niger* alpha-amylase.

4.3. Expression in *A. niger* of wild-type and modified expression constructs of *A. oryzae* phospholipase A1 using the pGBFINPLA- vectors and of *A. niger* alpha-amylase using the pGBFINFUA- vectors

5 The pGBFINPLA- and pGBFINFUA- expression constructs, prepared in the former paragraph, were introduced in *A. niger* by transformation as described below and according to the strategy depicted in figure 5.

10 In order to introduce the eight pGBFINPLA- vectors (Table 8) in WT 2 and the three pGBFINFUA- vectors (Table 9) in WT 3, a transformation and subsequent selection of transformants was carried out as described in WO98/46772 and WO99/32617. In brief, linear DNA of the pGBFIN constructs was isolated and used to transform *A. niger*. Transformants were selected on acetamide media and colony purified according standard procedures. Colonies were diagnosed for integration at the *glaA* locus and for
15 copy number using PCR. Five to ten independent transformants of each pGBFIN construct with similar estimated copy numbers (low copy: 1-2) were selected and named using the number of the transforming plasmid, as for example PLA-1a-1, PLA-1b-2 and FUA-1-1, FUA-3-1, respectively.

20 The selected PLA- and FUA- strains and *A. niger* WT 2 and WT 3 were used to perform shake flask experiments in 100 ml of the medium as described above for each of the protein products at 34 °C and 170 rpm in an incubator shaker using a 500 ml baffled shake flask. After 2, 3, 4, 5 and/or 6 days of fermentation, samples were taken.

25 In a first step, the *pla1* and *amyA* over-expression was measured by Northern blot analysis of the transformants of *A. niger* WT 2 and WT 3 and WT2 and WT 3 themselves. The collected mycelium was used for isolation of RNA (as described in WO99/32617) and Northern blot analysis following the standard procedures of Northern blot analysis (Sambrook et al., 1989). For all transformants of the wild-type *pla1* gene, but not for WT2 itself, a strong and comparable hybridization signal was detected for the *pla1*
30 mRNA level (data not shown). This indicates that the transcriptional control of the *pla1* gene by the glucoamylase promoter in all transformed strains of pGBFINPLA-1a until pGBFINPLA-1c was intact and unchanged compared to the wild-type *glaA* promoter. Additionally, *pla1* over-expression of the *pla1* modified constructs was measured by Northern blot analysis of the concerning PLA transformants of *A. niger* WT 2 and WT2

itself. For all transformants of the modified synthetic pla1 genes, but not for WT2 itself, a strong and comparable hybridization signal was detected (data not shown). This indicates that the transcriptional control of the optimized pla1 genes by the glucoamylase promoter in all transformed strains of pGBFINPLA-1d until pGBFINPLA-1h was intact and that the synthetic pla1 genes were expressed.

In a similar way, the *amyA* over-expression of the native and modified constructs was measured by Northern blot analysis of the concerning FUA transformants of *A. niger* WT 3 and WT3 itself, using a (universal) probe located in the 3'-untranslated region of the glucoamylase terminator used in all three expression constructs. For all transformants of *amyA* constructs, a strong and comparable hybridization signal was detected (data not shown). This indicates that the transcriptional control of the optimized *amyA* genes by the alpha-amylase promoter in all transformed strains of pGBFINFUA-1 to pGBFINFUA-3 was intact and that the synthetic *amyA* genes were expressed.

The production of phospholipase A1 polypeptide was measured in all *A. niger* PLA transformants. As can be seen in Figure 7, a positive effect of the use of a modified translation initiation site (variant 1 and variant 2) on phospholipase production can be observed using the glucoamylase promoter. Similarly, a positive effect of modification of codon usage and the translation stop sequence on phospholipase production was observed. A summary of the results is shown in Table 10 below. This indicates clearly how a single modification or a combination of modifications of the invention, for example a modified translation initiation sequence, such as variant 1, 2 or the variant described in US6,461,837 B1, and/or a modified codon usage and/or a modified translation stop sequence can be used to improve the yield of production of the phospholipase A1 in *A. niger*.

Table 10. Relative average phospholipase activities compared to wild-type construct for modified *pla1* control and coding sequences (as concluded from Figure 7).

5

Plasmid name	SEQ ID NO	Translational initiator sequence	Translational initiator coding sequence	Optimized codon frequency	Translational termination sequence	Average production Fig 7	Average production Fig 8
PGBFINPLA-1a	8	CACCTCAGCA	w.t	w.t	w.t	100 %	100 %
PGBFINPLA-1b	9	CACCGTCAAA	w.t	w.t	w.t	170 %	130 %
PGBFINPLA-1c	10	CGCAGTCAAG	w.t	w.t	w.t	130 %	
PGBFINPLA-1d	11	CACCTCAGCA	TTCTCTCTC	modified	TAAATA	170 %	
PGBFINPLA-1e	12	CACCGTCAAA	TTCTCTCTC	modified	TAAATA	230 %	240 %
PGBFINPLA-1f	13	CGCAGTCAAG	TTCTCTCTC	modified	TAAATA	260 %	
PGBFINPLA-1g	14	CACCGTCAAA	GCTTCCTTC	modified	TAAATA	230 %	
pGBFINPLA-1h	35	US 6,461,837 B1	TTCTCTCTC	modified	TAAATA	230%	

As can be learned from Figure 8, also in a multi-copy (2) situation the improvement clearly can be found. This indicated clearly how a single modification or a combination of modifications of the invention, for example a modified translation initiation sequence and/or a modified codon usage and/or a modified translation stop sequence can be used for improved production of the phospholipase A1 in *A. niger*.

The production of alpha-amylase was measured in all three different *A. niger* FUA transformants. As can be learned from Figure 9, a positive effect of the use of a modified translation initiation site (variant 1) on alpha-amylase production can be observed, using the alpha-amylase promoter. Additionally, a positive and synergistic effect of combination

of a modified translation initiation site (variant 1) with a modified codon usage and a modified translation stop sequence on improved alpha-amylase production was observed. These results indicate clearly the universal effect of the modification since both phospholipase production and alpha-amylase production can be improved using a
5 method of the invention. Additionally, multiple promoters could be improved using a modified translation initiation site of the invention. Clearly, these examples show how a single or a combination of modifications of the invention, for example a modified translation initiation sequence, a modified codon usage and/or a modified translation stop
10 sequence can be used for improved production of the alpha-amylase in *A. niger* or any other protein of interest in a filamentous fungus.

Applicant's or agent's file reference number 24402WO	International application No.
--	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description Firstly mentioned on page 8 line 29.	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution CENTRAAL BUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Uppsalalaan 8 P.O. Box 85167 NL-3508 AD Utrecht The Netherlands	
Date of deposit 10 August 1988	Accession Number CBS 513.88
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
We inform you that the availability of the microorganism identified above, referred to Rule 13bis PCT, shall be effected only by issue of a sample to an expert nominated by the requester until the publication of the mention of grant of the national patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only



This sheet was received with the international application

Authorized officer

S. Aulbeys
Sofina Aulbeys

For International Bureau use only



This sheet was received by the International Bureau on:

Authorized officer

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof.

5

A reference herein to a patent document or other matter which is given as prior art is not to be taken as an admission that that document or matter was known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A nucleotide sequence comprising:

- a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, said synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon;

wherein the optimized codon frequency is such that at least three native codons; more preferably 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, and most preferably at least 95% of the native codons have been exchanged with a synonymous codon, the synonymous codon changing the codon frequency such that the value of the absolute difference between the percentage for said synonymous codon in said frequency and the listed optimal percentage becomes smaller after modification, applying the following list of optimal percentages: cysteine by TGC (100%); phenylalanine by TTC (100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by AAC (100%); glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by GCT (38%) GCC (51%), or GCG (11%); aspartate by GAC (64%); glutamate by GAG (74%); glycine by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC (73%); leucine by TTG (13%), CTT (17%), GTC (38%), CTG (32%); proline by CCT (36%), CCC (64%); arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG (14%), AGC 21% threonine by ACT (30%), ACC (70%) and/or valine by GTT (27%), GTC (54%), GTG (19%);

and optionally said nucleotide sequence comprising control sequences such as:

- one translational termination sequence orientated in 5' towards 3' direction selected from the following list of sequences: TAAG, TAGA and TAAA, preferably TAAA, and/or

- one translational initiator coding sequence orientated in 5' towards 3' direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC; GCTGCCCCC; GCTCCCTCC; GCTCCCCTTC; GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC; GCTTCCTC; and GCTTCCTTC, preferably GCTTCCTTC.

Table 1: Optimal filamentous fungal codon frequency for synonymous codons in %

	.T.	.C.	.A.	.G.	
--	-----	-----	-----	-----	--

T..	Phe 0	Ser 21	Tyr 0	Cys 0	..T
T..	Phe 100	Ser 44	Tyr 100	Cys 100	..C
T..	Leu 0	Ser 0	Stop 100	Stop 0	..A
T..	Leu 13	Ser 14	Stop 0	Trp 100	..G
C..	Leu 17	Pro 36	His 0	Arg 49	..T
C..	Leu 38	Pro 64	His 100	Arg 51	..C
C..	Leu 0	Pro 0	Gln 0	Arg 0	..A
C..	Leu 32	Pro 0	Gln 100	Arg 0	..G
A..	Ile 27	Thr 30	Asn 0	Ser 0	..T
A..	Ile 73	Thr 70	Asn 100	Ser 21	..C
A..	Ile 0	Thr 0	Lys 0	Arg 0	..A
A..	Met 100	Thr 0	Lys 100	Arg 0	..G
G..	Val 27	Ala 38	Asp 36	Gly 49	..T
G..	Val 54	Ala 51	Asp 64	Gly 35	..C
G..	Val 0	Ala 0	Glu 26	Gly 16	..A
G..	Val 19	Ala 11	Glu 74	Gly 0	..G

2. A nucleotide sequence according to claim 1, wherein the codon fitness of the synonymous nucleotide coding sequence with optimized codon frequency has a fitness value

that is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%, and most preferable >98%, where the codon fitness is the calculated by means of the following function:

$$fit_c(g) = 100 - \frac{1}{|g|} \cdot \sum_{k=1}^{|g|} |r_c^{target}(c(k)) - r_c^g(c(k))| \cdot 100$$

where g symbolizes a nucleotide coding sequence, $|g|$ its length, $g(k)$ its k -th codon, $r_c^{target}(c(k))$ is a desired ratio of codon $c(k)$ and $r_c^g(c(k))$ an actual ratio in the nucleotide coding sequence g .

3. A synonymous nucleotide coding sequence with a codon fitness as defined in claim 2, wherein said synonymous nucleotide coding sequence is reverse engineered from an amino acid sequence.

4. A nucleotide sequence comprising a synonymous nucleotide coding sequence according to any one of claims 1 to 3, wherein the synonymous nucleotide coding sequence comprises a signal sequence.

5. A nucleotide sequence comprising at least one intron and a synonymous nucleotide coding sequence according to any one of claims 1 to 4.

6. A nucleotide sequence, according to any one of claims 1 to 5, comprising a translational initiator sequence, said translational initiator sequence comprising the nucleic acid sequence as defined by the consensus translational initiator sequence: 5'-mwChkyCAmv-3' (i.e. SEQ ID NO: 16), using ambiguity codes for nucleotides: m (A/C); r (A/G); w (A/T); s (C/G); y (C/T); k (G/T); v (A/C/G); h (A/C/T); d (A/G/T); b (C/G/T); n (A/C/G/T), preferably the consensus translational initiator sequence is one selected from the following list, 5'-mwChkyCAAA-3' (i.e. SEQ ID NO: 17), 5'-mwChkyCACA-3' (i.e. SEQ ID NO: 18), and 5'-mwChkyCAAG-3' (i.e. SEQ ID NO: 19).

7. A nucleotide sequence according to claim 7, wherein the translational initiator sequence is 5'-CACCGTCAAA-3' (i.e. SEQ ID NO: 22) or 5'-CGCAGTCAAG-3' (i.e. SEQ ID NO 23).

8. A nucleic acid construct comprising a nucleotide sequence according to any one of claims 1 to 7.

9. A filamentous fungal host cell comprising at least one copy of the nucleic acid construct of claim 8.

10. A filamentous fungal host cell according to claim 9 wherein the coding and/or control sequences present in the nucleic acid construct are native to the host cell before modification of the coding and/or control sequences as described in any one of claims 1 to 7.

11. A filamentous fungal host cell according to claim 9, wherein the coding and/or control sequences present in the nucleic acid construct are heterologous to the host cell before modification of the coding and/or control sequences as described in any one of claims 1 to 7.

12. A filamentous fungal host cell according to any one of claims 9 to 11, comprising a given copy number of the nucleic acid construct as defined in claim 8, wherein the expression of the product encoded by said nucleic acid construct is enhanced as compared to the production of the same product encoded by the corresponding nucleic acid construct comprising the corresponding native nucleotide sequences, said corresponding nucleic acid construct being present in the same copy number in the corresponding filamentous fungal host cell.

13. A filamentous fungal host cell according to any one of claims 9 to 12, which is an *Aspergillus*, *Trichoderma*, *Fusarium*, *Chrysosporum* or *Penicillium* species.

14. An *Aspergillus*, *Trichoderma*, *Chrysosporum* or *Penicillium* host cell according to claim 13, which is an *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus sojae*, *Aspergillus terreus*, or *Trichoderma reesei*, or *Chrysosporum lucknowense*, or *Penicillium chrysogenum*.

15. A method for producing a compound of interest and optionally purifying it by using the filamentous fungal host cell of any one of claims 9 – 14, comprising

- cultivating said filamentous fungal host cell in a nutrient medium suitable for production of the compound of interest, and
- recovering the compound of interest from the nutrient medium of the filamentous fungal host cell.

16. A method according to claim 15, wherein the yield of the compound of interest produced by the filamentous fungal host cell of the invention comprising a given copy number

of the nucleic acid construct as defined in claim 10 is increased by at least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400%, more preferably at least 500%, as compared to the production of the same compound of interest produced by the corresponding filamentous fungal host cell comprising the corresponding nucleic acid construct comprising the corresponding native nucleotide sequences, said corresponding nucleic acid construct being present in the same copy number in the corresponding filamentous fungal host cell.

17. A method according to claim 15, wherein production of the compound of interest in the filamentous fungal cell of any one of claims 13 to 14 results in a production of 0.1 g per liter, 0.2 g, 0.3 g, 0.4 g, more preferably 0.5 g and most preferably more than 0.5 g per liter of the compound of interest.

18. Use of any one of the nucleotide sequences of any one of claims 1 to 7, in a method for producing a compound of interest.

19. Use of a nucleic acid construct of claim 8, in a method for producing a compound of interest.

20. Use of any one of the filamentous fungal host cells of any one of claims 9 to 14 in a method for producing a compound of interest.


21. A method for producing a nucleotide sequence comprising the steps of:

- providing a synonymous nucleotide coding sequence with optimized codon frequency as defined in claims 1 to 5, and optionally
- operably linking said synonymous nucleotide coding sequence to a control sequence as defined in claim 1.

22. A method for producing a nucleotide sequence as defined in any one of claims 6 to 7.

23. A method for producing a nucleotide sequence as defined in claims 21 and 22.

24. A nucleotide sequence according to claim 1, substantially as hereinbefore described with reference to any of the examples and/or figures.

**Figure 1**




Figure 2





Figure 3

*Figure 4*




Figure 5

Native *pla* 1 CDS ATGTTTAGTCTCGCCGATTGGGGACCGTTGCAGGTCTATTTTAACTGGCTCAGGCTGCC
pla 1 genomic seq ATGTTTAGTCTCGCCGATTGGGGACCGTTGCAGGTCTATTTTAACTGGCTCAGGCTGCC
Modified *pla* 1 CDS ATGTTCTCTCTCGCCGCTTGGTACCGTCTGCTGGTCTCTCTCTCTGGCTCAGGCTGCC

Native *pla* 1 CDS CCGGCTTCACTGCGCAGAGG
pla 1 genomic seq CCGGCTTCACTGCGCAGAGGGTATGTTTATTTTCTCCACAACTTGTAACACAGGATTTCGGT
Modified *pla* 1 CDS CCGGCTTCCCTGCGCCGTG

Native *pla* 1 CDS ATGTCAAGCTCTTCCCTTCTCAATAACCTGGATCTCTTT
pla 1 genomic seq TGAAGCCAGACTGACGGATTTAGATGTCAAGCTCTTCCCTTCTCAATAACCTGGATCTCTTT
Modified *pla* 1 CDS ACGTCTCTCTTCCCTTCTCAAGAACCTGGACTCTCTT

Native *pla* 1 CDS GCACAGTACAGCGCCGCGGCATACGTGTGATGAGAACCTGAACCTCTACGGGGACCAAGTTG
pla 1 genomic seq GCACAGTACAGCGCCGCGCGCATACGTGTGATGAGAACCTGAACCTCTACGGGGACCAAGTTG
Modified *pla* 1 CDS GCTCAGTACAGCGCCGCGCGCTTACGTGATGAGAACCTGAACCTCTACGGGTACCAAGTTG

Native *pla* 1 CDS ACATGCTCTGTTGGCAACTGTCCTTTGGTAGAAGCGGCCTCTACCCAATCATTTGGATGAA
pla 1 genomic seq ACATGCTCTGTTGGCAACTGTCCTTTGGTAGAAGCGGCCTCTACCCAATCATTTGGATGAA
Modified *pla* 1 CDS ACCTGTCTCTGTTGGCAACTGCCCTCTGTGAGAGCGGCCTCTACCAGTCTCTTTGGATGAG

Native *pla* 1 CDS TTCAAAGA
pla 1 genomic seq TTCAAAGAGTAAGTCACCGCAAAATATACAATTCTAGTTTCATAAGCAACTACTGACAACTC
Modified *pla* 1 CDS TTCAAAGA

Native *pla* 1 CDS ATCGTCACTCTACGGCAACCCCGCGGGTACCTCGCGCTGATGAGACTAACAAAGCTC
pla 1 genomic seq AATCGTCACTCTACGGCAACCCCGCGGGTACCTCGCGCTGATGAGACTAACAAAGCTC
Modified *pla* 1 CDS AATCGTCTCTCTACGGCAACCCCGCGGTTACCTCGCGCTGACGAGACTAACAAAGCTC

Native *pla* 1 CDS CTAGTCTGTCTTCCGGGGTAGCGCTGACTTGCCAAATGGGTGCGCAACCTGAAATTT
pla 1 genomic seq CTAGTCTGTCTTCCGGGGTAGCGCTGACTTGCCAAATGGGTGCGCAACCTGAAATTT
Modified *pla* 1 CDS CTCGTCTGTCTTCCGTGGTAGCGCTGACTTGCCAACTGGGTGCGCAACCTGAATCTT

Native *pla* 1 CDS GGTCTCGAGGATGCCAGCGATCTGTGTTCTGGGTGCGAAGTGACACAGCGGCTTCTGGAAAG
pla 1 genomic seq GGTCTCGAGGATGCCAGCGATCTGTGTTCTGGGTGCGAAGTGACACAGCGGCTTCTGGAAAG
Modified *pla* 1 CDS GGTCTCGAGGACGCCAGCGATCTGTGCTCTGGTGTGCGAAGTCCACTCCGGCTTCTGGAAAG

Native *pla* 1 CDS GCATGGAGTGAAATCGCCGACACCATCACTTCCAAAGTGGAAATCAGCTTTGTGGATCAT
pla 1 genomic seq GCATGGAGTGAAATCGCCGACACCATCACTTCCAAAGTGGAAATCAGCTTTGTGGATCAT
Modified *pla* 1 CDS GCTTGGTCTGAGATCGCCGACACCATCACTTCCAAAGTGGAAATCCGCTTTGTGGATCAC

Native *pla* 1 CDS TCCGATTATTCTTGGTCTTGACCGGACATAGTTACGGCGCTGCGCTGGCAGCCCTCGC
pla 1 genomic seq TCCGATTATTCTTGGTCTTGACCGGACATAGTTACGGCGCTGCGCTGGCAGCCCTCGC
Modified *pla* 1 CDS TCCGATTACTCCTTGGTCTTGACCGGTCACTCGTACGGCGCTGCGCTGGCAGCCCTCGC

Native *pla* 1 CDS AGCGACTGCTCTGGGAACTCCGGCCATAGTTGTTGAGCTG
pla 1 genomic seq AGCGACTGCTCTGGGAACTCCGGCCATAGTTGTTGAGCTGGTAAGTTATCTCTATTTTG
Modified *pla* 1 CDS CGCGACTGCTCTGGTAACCTCCGGCCACTCGGTTGAGCTG





Figure 6

**Figure 7**





Figure 8

**Figure 9**

EDITORIAL NOTE -2006207463

The Sequence Listing for this application has been submitted to WIPO in electronic format and can be obtained upon request from the International Bureau or found on the WIPO website at <http://www.wipo.int/pct/en/sequences/listing.htm>